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ABSTRACT 
 
Elizabeth Chase Lessey-Morillon: The RhoA guanine nucleotide exchange factor, 
LARG, mediates ICAM-1-dependent mechanotransduction in endothelial cells to 
stimulate transendothelial migration 
(Under the direction of Keith Burridge) 
RhoA-mediated cytoskeletal rearrangements in endothelial cells (ECs) play 
an active role in leukocyte transendothelial cell migration (TEM), a normal 
physiological process in which leukocytes cross the endothelium to enter the 
underlying tissue. While much has been learned about RhoA signaling pathways 
downstream from ICAM-1 in ECs, little is known about the consequences of the 
tractional forces that leukocytes generate on ECs as they migrate over the surface 
before TEM. We have found that after applying mechanical forces to ICAM-1 
clusters, there is an increase in cellular stiffening and enhanced RhoA signaling 
compared to ICAM-1 clustering alone. We have identified that the Rho GEF 
LARG/ARHGEF12 acts downstream of clustered ICAM-1 to increase RhoA activity 
and that this pathway is further enhanced by mechanical force on ICAM-1. Depletion 
of LARG decreases leukocyte crawling and inhibits TEM. This is the first report of 
endothelial LARG regulating leukocyte behavior and EC stiffening in response to 
tractional forces generated by leukocytes.  
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Chapter 1: BACKGROUND AND SIGNIFICANCE 
 
Leukocyte Transendothelial cell migration 
Endothelial cells (ECs) make up the lining of blood vessels and provide a 
protective barrier to the underlying tissue. Dynamic regulation of the ECs and cell-
cell junctions is required to allow leukocyte diapedesis. During inflammation or 
infection, chemoattractant signaling cues the leukocytes to exit the blood stream  
(Figure 1). Pro-inflammatory signaling increases expression of adhesion receptors, 
including E-selectin, ICAM-1, and VCAM-1, on the luminal surface of the EC (1-4). 
These adhesion molecules bind to receptors on the leukocyte. For example, E-
selectin binds to sialylated glycoproteins on leukocytes (5), whereas ICAM-1 binds to 
β2 integrins such as leukocyte function-associated molecule-1 (LFA-1)(αLβ2, 
CD11a/CD18) (6, 7), and macrophage-1 antigen (Mac-1) (αMβ2CD11b/CD18) (8, 9), 
and VCAM-1 binds to β1 integrins such as very late antigen-4 (VLA-4) (α4β1, 
CD49a/CD29) (10).  
Initially, the leukocyte loosely binds to the surface of the endothelium (Figure 
1A). The endothelial adhesion receptors that bind to the leukocyte during this initial 
stage are selectins, chiefly E-selectin. The leukocyte rolls over the endothelium due 
to the force of the blood flow and the weak adhesion between the leukocyte and the 
endothelial surface. The loss of E-selectin reduces leukocyte adhesion following 
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inflammation (11). While E-selectin binds the leukocyte to slow it down from the 
circulation, E-selectin also links to the endothelial cytoskeleton to alter EC signaling 
(12). 
 
Figure	  1:	  Steps	  in	  Leukocyte	  TEM	  	  
(A)	  The	  leukocyte	  loosely	  adheres	  to	  the	  endothelium.	  (B)	  Then,	  the	  leukocyte	  spreads	  and	  crawls.	  (C)	  Lastly,	  
the	  leukocyte	  crosses	  the	  endothelium	  at	  an	  EC	  junction,	  paracellular	  migration,	  or	  though	  an	  EC,	  
transcellular	  migration.	  
Next, the leukocyte binds to other adhesion receptors, including ICAM-1, then 
spreads and crawls on the endothelial surface (Figure 1B). ICAM-1 engagement 
initiates many signaling pathways within the EC to assist in leukocyte TEM 
(discussed later in this chapter) (13-21). The crawling leukocyte extends protrusions 
to probe the surface of the endothelium (20). Transmigration can occur by two 
routes, transcellular and paracellular diapedesis (Figure 1C) (22-24). Paracellular 
migration is the most well studied route of diapedesis and occurs by the leukocyte 
migrating through the junction between two ECs. For a leukocyte to be able to cross 
at an endothelial cell-cell junctions the junctional proteins must disengage (25-27). 
Leukocyte bindings to adhesion receptors on the EC surface induces the junctions to 
weaken (28). The alternative route is transcellular diapedesis, where a leukocyte 
migrates through a single EC. Like in paracellular migration, leukocyte engagement 
of EC receptors initiates the process. A combination of actin protrusions and vesicle 
B. 
A. 
C. 
Rolling
Loose adhesion Firm Adhesion
Spreading/Crawling
Migration
ECs
Leukocyte ICAM-1
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trafficking create pore in the ECs allowing the leukocyte to pass through (18, 29, 30). 
Both routes depend on endothelial changes in the cytoskeleton, which are controlled 
by Rho GTPases (14, 15, 30, 31), 
The Rho Family of Small GTPase-binding proteins 
Rho GTPases are a subfamily of the Ras superfamily of GTPases, which act 
as molecular switches. By cycling through an on/off cycle, they are able to regulate 
the cytoskeleton and cell contractility. There are 22 members of the Rho family in 
mammals (32). The most well studied family members are RhoA, Rac1 and CDC42. 
RhoA promotes stress fibers and actomyosin contractility (33, 34). Rac1 stimulates 
actin polymerization and induces the branched actin network that makes up the 
lamellipodia at the leading edge of a cell (33). Cdc42 also stimulates actin 
polymerization and regulates protrusions known as filopodia (35, 36). In addition, 
these GTPases regulate many other activities (37). 
 
Figure	  2:	  RhoA	  cycle	  
Like	  most	  G	  proteins,	  RhoA	  cycles	  between	  an	  inactive	  
GDP-­‐bound	  form	  and	  an	  active	  GTP-­‐bound	  form.	  
Activation	  is	  mediated	  by	  GEFS	  that	  catalyze	  
exchange	  of	  GDP	  for	  GTP.	  GAPs	  inactivate	  RhoA	  by	  
stimulating	  intrinsic	  GTPase	  activity.	  GDI	  sequesters	  
inactive	  GDP-­‐bound	  RhoA	  in	  the	  cytoplasm.	  
	  
 
Rho GTPases are activated by guanine nucleotide exchange factors (GEFs), 
which induce conformational changes in Rho GTPases that promote the exchange 
of GDP for GTP. With GTP bound, Rho GTPases interact with downstream effectors 
to initiate signaling cascades, which then lead to cytoskeletal changes (Figure 2). 
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Rho GTPases are inactivated by GTPase-activating proteins (GAPs) that enhance 
the intrinsic GTPase activity by stimulating hydrolysis of GTP to GDP. It is striking 
that there are more GEFs or GAPs than Rho family members. This most likely 
reflects that many signaling pathways can converge on individual Rho proteins and 
that different GEFs and GAPs function within these different pathways.  
Some redundancy between GEFs appears to exist and is indicated by the 
modest or negligible phenotype induced in mice where a single GEF has been 
knocked out. PDZ-RhoGEF knockout mice or LARG knockout mice have no obvious 
phenotype, but the double knockout is lethal suggesting compensation between the 
GEFs in the single knockout mice (38). Also, LARG deficient mice have a lower than 
expected birth rate which might be a result of GEF compensation in the surviving 
mice (38). A close examination of Vav deficient mice show that compensation 
between GEFs, even closely related isoforms, does not always occur. Only Vav1, 
not Vav2 or Vav3, regulates thymic selection based the phenotype of the single 
isoform knockout animals (39-42).  When Vav1 and Vav3 are knocked out, there is 
further impairment of thymic selection, suggesting that Vav3 is compensating for 
Vav1 (39, 40). However, Vav2 is unable to do so as the double Vav1 and Vav2 
knockout mice have the same thymic selection defect as the single Vav1 knockout 
mice (43). While single GEF knockout animals frequently lack a strong phenotype, 
the Trio knockout mice are not viable from a neuronal and muscle defect (44). 
The hallmark of most RhoGEFs is the dbl homology (DH) region. The DH 
domain, located at the C-terminal, is the region responsible for the GEF activity. The 
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DH domain is able to bind inactive Rho and induce dissociation of GDP, temporally 
leaving Rho in a nucleotide-free state. However, due the high ratio of GTP to GDP 
within the cell, GTP quickly binds, thus transferring Rho into its active state. The 
neighboring pleckstrin homology (PH) domain can associate with phosphoinositides 
causing plasma membrane localization as well as assisting with GTPase binding.  
The DH-PH domain is also responsible for the specificity of GEFs for Rho GTPases. 
A single DH-PH domain can exchange nucleotide for a specific GTPases or can act 
on multiple GTPases. For example, Leukemia-associated Rho guanine nucleotide 
exchange factor (LARG) can only activate RhoA (45) while Vav shows less 
specificity and can activate RhoA, Rac, Cdc42 and RhoG (46). Some GEFs like, 
Trio, have multiple DH-PH domains each with different Rho family specificities (47).  
GAP proteins are not as well characterized as GEFs but are just as important 
in understanding Rho GTPase function. The first identified GAP was Rho GAP (48). 
Subsequent family members have been identified by the presence of the GAP 
domain. The GAP domain binds to active GTP-bound Rho proteins and promotes 
hydrolysis of GTP to GDP, thus cycling Rho GTPases into their inactive form. Like 
GEFs, GAPs have specificities for Rho family members. This allows for tight 
regulation of the Rho GTPase family member.  
Rho GTPases control the cytoskeleton by signaling to downstream effector 
proteins. In their active state, Rho GTPases bind to effectors. The RhoA effector, 
Rho kinase (ROCK) regulates actomyosin contractility. ROCK signaling leads to 
phosphorylation of the myosin light chain (MLC) either directly or indirectly by 
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inactivating MLC phosphatase, which then causes increased actomyosin contractility 
(49-52). In some cells such as fibroblasts, the activation of myosin stimulates the 
formation of stress fibers (53). ROCK can also signal through LIM kinase to promote 
actin stress fiber formation. ROCK can activate LIM kinase, which then 
phosphorylates cofilin (54). Cofilin functions as an actin-severing protein and is 
inactivated after phosphorylation. Formins, including mammalian homolog of 
Drosophila diaphanous (mDia), are another class of Rho effectors that function  to 
promote stress fiber formation by nucleating actin polymerization to create F-actin 
(55). 
ICAM-1 Signaling 
One of the most-well studied adhesion receptors in Rho GTPases signaling during 
leukocyte TEM is ICAM-1. ICAM-1 has 5 extracellular IgG like domains and a small 
22 aa cytoplasmic tail (Figure 3). β2 integrins, such as LFA-1 or MAC-1, bind to 
specific IgG domains to induce ICAM-1 clustering. ICAM-1 is then translocated into 
the lipid insoluble regions (56). This clustering is then able to bring together the 
intracellular domains initiating downstream signaling cascades (57, 58).  
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Figure	  3:	  A	  diagram	  of	  
	  ICAM-­‐1	  
One central consequence of ICAM-1 clustering is 
rearrangement of the EC cytoskeleton, which assists in 
leukocyte TEM. This is predominantly due to increases in RhoA 
signaling and changes in the actin cytoskeleton (14-16, 59, 60). 
After ICAM-1 clustering, F-actin and actin binding proteins, 
including ezrin, moesin, radixin, and α-actinin, associate with the 
ICAM-1 complex to induce cytoskeletal changes (21, 31, 61-64). 
FAK, paxillin, p130Cas, ezrin, and cortactin are phosphorylated 
in response to ICAM-1 crosslinking (64, 65). Src phosphorylation 
also occurs and is responsible for cortactin phosphorylation (64). 
Interestingly, Src also becomes phosphorylated after E-selectin 
clustering (64). Leukocyte-induced ICAM-1 clustering activates 
RhoA to assist in migration across the EC monolayer (14-16, 59, 60). Inhibiting 
RhoA signaling in ECs greatly attenuates leukocyte adhesion, spreading, and 
migration (14, 15, 59, 60). RhoA signaling leads to activation of the effector Rho-
associated protein kinase (ROCK) (50). Rock dependent enhanced EC actomyosin 
contractility results in weakened cell-cell junctions allowing the formation of gaps 
through which leukocytes can migrate across the EC monolayer (49, 50).  
Paracellular migration 
Paracellular diapedesis is a well-studied route for leukocyte TEM and requires 
ECs to alter their cell-cell junctions to allow leukocytes to cross. Normally, adherens 
and tight junctions formed between neighboring ECs create a barrier to protect the 
Extracellular 
TM 
Intracellular 
 
 
 
 
 
 
 
D1 
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integrity of the blood vessel. Pro-inflammatory signaling can disrupt cell-cell junctions 
to increase permeability (23). Also, leukocyte binding to the EC induces a signaling 
cascade to weaken the cell-cell junctions to assist in diapedesis. 
Adherens junctions are central regulators of leukocyte TEM. One of the more 
well studied cell adhesion molecules found in adherens junctions is vascular 
endothelial-cadherin (VE-cadherin). VE-cadherin regulates the strength of EC 
junctions and is critical in leukocyte TEM (28). Significantly, VE-cadherin is a 
downstream target of RhoA-dependent contractility. The extracellular domain of VE-
cadherin creates a homophilic interaction with a VE-cadherin on a neighboring cell, 
and this interaction is calcium dependent (66). Blocking VE-cadherin increases 
leukocyte TEM (25, 26). Conversely, Mice expressing a mutant VE-cadherin-α-
catenin fusion protein, which prevents the disassociation of VE-cadherin at cell-cell 
junctions, leads to decreased permeability and leukocyte TEM (27). 
The dissociation and loss of VE-cadherin from adherens junctions during 
leukocyte TEM triggers cell-cell junctions to weaken allowing the leukocyte to cross, 
then VE-cadherin returns shortly after to reseal the junction (67, 68). 
Phosphorylation of VE-cadherin assists in the disruption of cell junctions (28, 69-71). 
Specifically, ICAM-1 crosslinking induces downstream signaling to phosphorylation 
of VE-cadherin by activating Src and pyk2 (28).  
Endothelial junctions also contain tight junction proteins that regulate 
leukocyte TEM as well. Endothelial tight junctions typically differ from tight junctions 
found in other cell types like epithelial cells. In epithelial cells tight junctions are 
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restricted apically, whereas in ECs tight junctions extend throughout the junction 
interface and intermingle with the adherens junction proteins (72). The role of tight 
junction proteins in leukocyte TEM has not been as extensively studied as the role of 
adherens junction proteins. However, phosphorylation of the tight junctional proteins 
occludin and claudin-5 are reported during leukocyte TEM, and depend on RhoA and 
ROCK signaling (73). Highly regulated control of junctional proteins is required for 
efficient leukocyte TEM. 
Transcellular migration 
Transcellular diapedesis is a less anticipated route for a leukocyte to cross 
the endothelium. Instead of crossing that the endothelial junctions, the leukocyte 
passes through a single EC. Transcellular diapedesis initially was observed in 
electron micrographs of leukocyte TEM occurring in in vivo models of inflammation 
(74, 75). This route is less well characterized than paracellular TEM but does involve 
some of the same adhesion receptors, like ICAM-1 (17, 18). After leukocyte 
adhesion, caveolin-1 co-localizes with the transcellular pore (18). ICAM-1 rich 
microvilli-like structures extend from the EC around the leukocyte before it ultimately 
transmigrates (17, 18, 20, 28, 30). 
Another Rho family member involved in leukocyte TEM is RhoG. van Buul et 
al. found the actin rich cups forming by the EC around the transmigrating leukocyte 
require RhoG activity (30). The RhoG GEF, SGEF, appears to be responsible for this 
process (30). It is worth noting the possibility of RhoA being involved in this process, 
as inhibiting RhoA expression prevents RhoG activation after ICAM-1 clustering (30).  
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It is unclear why transcellular or paracellular diapedesis becomes the chosen 
route for a leukocyte. However, it does appear that the EC type might play a role. 
Whereas in HUVECs there is very a small number of transcellular diapedesis events, 
less than 10%, it is as much as 30% in microvascular ECs (20).  The route picked 
might also be dependent on the type of stimulus to induce inflammation. Under pro-
inflammatory conditions, like treatment with VEGF, histamine, LPS or IL-1β, 
paracellular diapedesis occurs more frequently (27). While paracellular diapedesis 
frequently occurs at a higher rate, this does not rule out an important role for 
transcellular diapedesis. 
Summary 
Regardless of the transcellular or paracellular path the leukocyte takes, the 
endothelium is an active player in the process in part due to the role of Rho Family 
GTPases. The endothelial cytoskeleton is responding to endothelial receptors 
engaging with the leukocyte to assist in diapedsis. TEM illustrates the important role 
for Rho family GTPases in this example of cell-cell interactions, but TEM is also 
critical in the normal inflammatory response and in inflammatory diseases. 
Understanding the role of Rho GTPases in TEM may therefore provide insight into 
ways of regulating TEM and suggest potential therapies for controlling inflammation 
in disease situations. 
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Chapter 2: FROM MECHANICAL FORCE TO RHOA ACTIVATION1 
 
Throughout their lives all cells constantly experience and respond to various 
mechanical forces. These frequently originate externally but can also arise internally 
as a result of the contractile actin cytoskeleton. Mechanical forces trigger multiple 
signaling pathways. Several converge and result in the activation of the GTPase 
RhoA. In this review we focus on the pathways by which mechanical force leads to 
RhoA regulation, especially when force is transmitted via cell adhesion molecules 
that mediate either cell-matrix or cell-cell interactions. We discuss both the upstream 
signaling events that lead to activation of RhoA, as well as the downstream 
consequences of this pathway. These include not only cytoskeletal reorganization 
and, in a positive feedback loop, increased myosin-generated contraction, but also 
profound effects on gene expression and differentiation. 
 
                                            
 
1 This chapter appeared as a review article in Biochemistry. Reproduced with 
permission from Lessey, E. C., Guilluy, C., and Burridge, K. (2012) From Mechanical 
Force to RhoA Activation, Biochemistry 51, 7420-7432. Copyright 2013 American 
Chemical Society. 
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Introduction 
All cells are exposed to mechanical forces and to a greater or lesser degree 
responds to these forces. In the vertebrate body, cells experience different types of 
force according to their tissue location. For example, ECs lining blood vessels, as 
well as epithelial cells lining certain ducts or cavities, experience mechanical force 
from the passage of fluid over the cell surface. Cells in the skeletal system (bone 
and cartilage) but also many other cells are exposed to compression. Throughout 
most tissues, cells experience varying degrees of tension, which can arise from 
external forces or from within the cell as a result of actomyosin contractility. It is 
important to note, however, that the very high tensional forces experienced by some 
tissues, such as tendons and ligaments, are usually transmitted by extracellular 
matrix (ECM) components such as collagen fibers and the cells within these tissues 
are shielded from the tension by the ECM (76). Some forces on cells may be cyclical 
as experienced by cells in contact with the blood circulation, or as a result of 
rhythmic activities such as breathing or walking, whereas other cells experience 
sustained force for varying periods of time. 
Experiments exploring how cells respond to different types of mechanical 
force go back a long way. For example, in early experiments stretching cells was 
shown to stimulate their proliferation (77). Stretching of myotube cultures induced 
responses equivalent to muscle hypertrophy (78). The growth cones of elongating 
neurites were found to exert mechanical force (79) and to respond to externally 
applied forces (80). Similarly, fibroblasts and other cells were observed to generate 
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tractional forces on the underlying substratum (81) and to be able to harness these 
forces to orient collagen fibers (82). Application of mechanical tension to migrating 
cells in culture using a microneedle inhibited extension perpendicular to the axis of 
tension but allowed or even promoted extension that was parallel with the force (83). 
Although research in the field of mechanotransduction has been active for 
many years, much of it was focused on systems, tissues and cells that are very 
overtly affected by mechanical stimuli, such as vascular ECs and vascular smooth 
muscle exposed to flow and/ or stretch, or osteoblasts that experience compressive 
forces. However, during the past decade there has been an explosion of interest in 
the more universal responses of cells to mechanical forces and progress is occurring 
rapidly. Whether the forces are applied exogenously on cells or are generated 
endogenously, they are usually transmitted to the ECM or to neighboring cells via 
cell adhesion molecules. Consequently, considerable interest has been directed at 
understanding the signaling pathways that are initiated in response to mechanical 
forces that are applied to adhesion molecules (84). Multiple signaling pathways have 
been identified, including tyrosine kinases, ion channels and GTPases (85). One of 
the pathways that appears to be involved in many cells responding to mechanical 
force involves activation of Rho family GTPases, particularly RhoA. In this review we 
will focus primarily on the signaling pathways that lead to activation of RhoA in 
response to mechanical force and we will discuss the consequences of this pathway. 
The reader is directed to recent comprehensive reviews for information about 
mechanotransduction in various contexts (86-91). 
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The Rho pathway 
In contrast to most plant cells that have rigid cell walls, the mechanical 
properties of animal cells are critically dependent on their cytoskeletons, consisting 
of microtubules, actin microfilaments, various types of intermediate filaments and 
also septins (92). All of these filament systems may contribute to the mechanical 
properties of animal cells, although with respect to how cells respond to exogenously 
applied forces most attention has been directed toward the actin cytoskeleton. When 
actin filaments are highly crosslinked they can give rise to a relatively rigid cell 
cortex. However, this can be rapidly remodeled to allow cell protrusion and changes 
in cell shape. The polymerization of actin filaments drives many types of cell 
extension. In conjunction with myosin, actin filaments can generate contractile 
forces, exerting traction on the surrounding matrix or on other cells and contributing 
to major changes in cell morphology. The interaction of myosin with actin not only 
contributes to the response of cells to 
exogenously applied forces but is responsible 
for generating endogenous forces within cells. 
Figure	  4:	  RhoA	  effector	  signaling	  
Activated	  RhoA	  interacts	  with	  effector	  proteins,	  which	  lead	  
to	  actomyosin	  contractility	  and	  actin	  stabilization.	  ROCK	  
signals	  by	  MLC	  phosphorylation	  to	  increase	  myosin	  II	  
activity	  and	  LIM	  kinase	  to	  increase	  the	  level	  of	  actin	  
stabilization.	  mDia	  nucleates	  actin	  polymerization.	  
The Rho family of GTPases are key 
regulators of the actin cytoskeleton. The 
mammalian genome encodes approximately 
20 Rho GTPases, although the three ubiquitous ones, RhoA, Rac1 and Cdc42, are 
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the most studied and each has distinct effects on the actin cytoskeleton (33, 34). In 
the context of mechanotransduction, most effort has been directed at determining 
the role of RhoA, which is the focus of this review. In large part, this reflects the fact 
that RhoA regulates the activity of myosin II and consequently is responsible for 
much of the intracellular tension and force that is generated within cells (93). RhoA 
cycles between an inactive GDP state and an active GTP state (Figure 2). Three 
classes of proteins regulate this cycle: GEFs, GAPs and guanine nucleotide-
dissociation inhibitors (GDIs) (94). GEFs activate Rho proteins by catalyzing the 
exchange of GDP for GTP (32) and GAPs stimulate the intrinsic GTPase activity, 
leading to the return to the inactive state (95). The inactive pool of RhoA is 
maintained in the cytosol by association with GDI (96) and it is in the active GTP-
bound conformation that RhoA interacts with its effectors and performs its functions 
(Figure 2). With respect to regulating the activity of myosin II, the critical effector is 
ROCK, which exists in two isoforms, ROCK1 and ROCK2. Both isoforms promote 
myosin II activity by elevating the phosphorylation of the regulatory MLC. This occurs 
both directly by phosphorylation of the regulatory MLC (51) and indirectly by 
phosphorylation and consequent inhibition of the MLC phosphatase (52). The 
phosphorylation of the MLC promotes assembly of myosin II into bipolar filaments 
and enhances the ATPase activity of myosin II. Together these effects increase the 
contractile force generated by myosin II on actin filaments. ROCK also 
phosphorylates and activates another kinase, LIM kinase, which in turn 
phosphorylates and inhibits the actin-severing protein cofilin (54). By inhibiting 
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cofilin’s actin severing activity, this increases the stability of actin filaments. Active 
RhoA also promotes actin filament polymerization. This occurs by RhoA binding 
different effector, mDia1, which is member of the formin family of actin nucleating 
factors (55) (Figure 4). 
Figure	  5:	  Mechanical	  force	  in	  cell	  biology	  	  
Diagram	  summarizing	  the	  different	  types	  of	  force	  that	  cells	  can	  experience.	  These	  can	  be	  externally	  applied	  
(A)	  or	  generated	  by	  the	  cell	  itself	  and	  its	  own	  cytoskeleton	  (B).	  The	  effect	  on	  RhoA	  activity	  is	  indicated	  for	  
each	  example.	  Force	  is	  a	  vector	  with	  magnitude	  and	  direction	  that	  causes	  an	  object	  with	  mass	  to	  change	  its	  
velocity	  (units	  of	  newtons).	  Stress	  is	  force	  per	  unit	  of	  area	  (units	  of	  pascals).	  
	  
In the context of mechanical signals, one can distinguish two types of forces 
experienced by cells: (1) forces which are externally applied to the cells, such as the 
shear stress exerted by blood flow on the surface of ECs, or (2) forces which are 
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generated by the cell itself with its cytoskeleton (97, 98) (Figure 5). Despite the 
apparent differences between these two signals, applied forces and cell-generated 
forces share some similarities in their transduction modalities and seem to regulate 
the same molecular mechanisms (89, 98). In both cases, cell surface adhesions, 
cytoskeleton and membrane tension cooperate to transmit forces which eventually 
affect the conformation of “mechanosensors” and trigger the mechanoresponse (85, 
89). Interestingly, numerous GEFs and GAPs are known to associate with 
cytoskeletal and cell adhesion components, suggesting that mechanical forces can 
directly affect the activity or the localization of RhoA regulators. 
GEFs and GAPs 
  Some GEFs specific for RhoA have been found to associate with the 
cytoskeleton and adhesions (Table 1). Integrin-based adhesions constitute a major 
site of mechanotransduction (99) and experience very diverse types of forces. For 
example, they are subjected to tensional forces when the ECM is stretched or when 
cells are grown on rigid substrates and generate more myosin-dependent 
contractility (Figure 5). Therefore, it’s not surprising that the GEFs associated with 
Cell-ECM adhesions are involved in the mechanoresponse (Figure 6A). Among 
them, vav2 was reported to be phosphorylated and activated in response to cyclic 
stretch in mesangial cells (100). Vav2 phosphorylation required EGFR  
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GEFs Localization References 
p115 (ArhGEF1) Cell-ECM adhesion (101, 102) 
GEF-H1(ArhGEF2) Cell-ECM adhesion 
Cell-Cell adhesion 
Microtubule 
(101, 102) 
(103, 104) 
(105) 
LARG (ArhGEF12) Cell-ECM adhesion (101, 102) 
Vav Cell-ECM adhesion (106) 
p190RhoGEF Cell-ECM adhesion 
mirotubule 
(107) 
p114RhoGEF (ArhGEF18) Cell-Cell adhesion 
 
(107) 
Trio Intermediate filaments (108) 
PDZRhoGEF (ArhGEF11) Cell-ECM adhesion (109) 
 GAPs   
p190RhoGAP Cell-ECM adhesion (110) 
DLC1 Cell-ECM adhesion 
Cell-Cell adhesion 
 
(111) 
(112) Myo-IXA Cell-Cell adhesion (113) 
Table	  1:	  RhoA	  GEFs	  and	  GAPs	  which	  associate	  with	  the	  cytoskeleton	  or	  adhesions	  
 
transactivation. Depletion of vav2, as well as EGFR inhibition, prevented stretch-
induced RhoA activation (100). Applying tensional forces on fibronectin coated 
beads bound to fibroblasts, our group recently showed that force on integrins 
activates RhoA through two GEFs, GEF-H1 and LARG (101) (Figure 6B). 
Weobserved that mechanical forces induce the recruitment of GEF-H1 and LARG to 
the adhesions. We found that Fyn regulates LARG activity, whereas GEF-H1 is 
activated by a FAK/Ras/ERK signaling pathway. Consistent with these findings, 
Waterman and colleagues observed that myosin- dependent contractility promotes 
GEF-H1 recruitment to Cell-ECM adhesions (114). Interestingly, another group found 
that GEF-H1 is more active when epithelial cells are grown on rigid substrates (115). 
This suggests that both externally applied forces and cell- generated forces activate 
the same GEFs, reinforcing the idea that these two distinct mechanical signals 
trigger the same signaling pathways. However, on rigid substrates, Heck and 
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colleagues observed that microtubule stability, and not the Ras/ERK pathway, 
regulates GEF-H1 activity (115). This apparent discrepancy could be due to the 
difference of cell types that were used in these studies. Indeed, working with 
fibroblasts another group observed that RhoA activation in response to stretch was 
not affected by taxol-induced microtubule stabilization (116), whereas in ECs RhoA 
activation in response to stretch requires GEF-H1 and is prevented by taxol (117).  
Figure	  6:	  RhoA	  GEFs	  and	  GAPs	  regulated	  by	  force	  
(A)	  Schematic	  diagram	  showing	  the	  GEFs	  and	  GAPs	  whose	  activities	  are	  regulated	  by	  external	  force	  or	  cell-­‐
generated	  tension	  on	  cell–ECM	  adhesions.	  (B)	  Diagram	  showing	  the	  signaling	  pathways	  that	  regulate	  GEF-­‐
H1	  and	  LARG	  activity	  in	  response	  to	  force	  on	  integrin	  (31).	  
 Cell-cell adhesions are also subjected to tensional forces which are generated 
by neighboring cells or by the cell’s own contractile machinery (Figure 5). It is now 
clear that tugging forces play an important role in intercellular junction maturation 
and growth (see below) (118-120). Interestingly, some RhoA GEFs have been found 
to localize at intercellular adhesions. GEF-H1 associates with cingulin at tight 
junctions (103, 104), however this interaction was reported to inhibit GEF-H1 and 
RhoA. More recently, p114RhoGEF was shown to localize at tight junctions and to 
activate RhoA locally, leading to junction assembly (121). Since mechanical tension 
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induces junction maturation (118), it would be interesting to determine if 
p114RhoGEF activity is regulated by tugging forces. 
Mirroring the GEFs, some RhoA GAPs localize at adhesions (Table 1) and play a 
role during the mechanoresponse. DLC1 (111, 122-124) and p190RhoGAP (125-
128) associate with Cell-ECM adhesion components. Shear stress regulates 
p190RhoGAP activity in a biphasic pattern in ECs (129). It was found that short term 
application of shear stress (<5 min) activates p190RhoGAP through Src Family 
Kinase-mediated phosphorylation, but longer application of shear stress (>30 min) 
induces p190RhoGAP dephosphorylation and inactivation. This biphasic regulation 
of p190RhoGAP leads first to RhoA inactivation followed by activation, similar to 
what has been observed during adhesion to matrix. Interestingly, p190RhoGAP is 
necessary for stress fiber alignment in response to shear stress (52). In addition, 
p190RhoGAP was shown to be necessary for the regulation of two transcription 
factors, GATAII and TFII-I, in response to increased matrix rigidity in a model of 
capillary tube formation (130). This suggests that cell-generated contractility may 
affect p190RhoGAP activity, although this remains to be determined. More recently, 
Myo-IXA, a single headed myosin with a GAP domain, has been shown to associate 
with actin at cell- cell junctions, locally restraining RhoA activity to allow proper 
junction formation (113). It would be interesting to analyze if application of tensional 
force on intercellular junctions affects Myo-IXA activity or localization. 
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Other Rho proteins 
There is extensive crosstalk between RhoA and Rac1 that contributes to 
processes such as cell migration (131). In the context of mechanotransduction 
several pathways have been identified, particularly where high RhoA activity and 
mechanical tension may depress Rac1 activity. During polarized migration it is 
important to confine protrusion to the front of the migrating cell and to suppress 
inappropriate protrusions at other sites on a cell’s periphery. Recent studies have 
implicated membrane tension generated during cell migration in the suppression of 
Rac1 activity at sites away from the leading edge and in the maintenance of cell 
polarity during migration (132). Several potential pathways are suggested by 
previous work. In migrating leukocytes, high RhoA/ROCK activity was shown to 
restrict membrane protrusion to the leading edge, in part via the LIM kinase pathway 
inhibiting cofilin and thereby stabilizing actin filaments at the cell periphery away 
from the cell front (133). In other work, inhibiting the Rac GAP FilGAP was found to 
increase membrane protrusions around the periphery of cells (134) suggesting that 
this Rac GAP confines protrusion to the cell front. Interestingly, FilGAP activity was 
activated by ROCK-mediated phosphorylation, providing a mechanism by which high 
RhoA activity can inhibit Rac1 activity. In a subsequent study using a reconstituted 
actin gel with several purified proteins, it was shown that FilGAP dissociates from 
filamin A in response to mechanical tension (135). When released it was suggested 
to relocate to the plasma membrane where it can act to inhibit Rac1 activity. The 
related Rac GAP, ArhGAP22, is activated in cells by endogenous mechanical force 
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to depress Rac1 activity (60). Blocking myosin activity, either directly with 
blebbistatin or indirectly by inhibiting ROCK activity, decreased ArhGAP22 
activity(136). The Rac GEF βPIX binds to Myosin II and actomyosin contractility 
induces βPIX dissociation from cell substrate adhesions (114). This contributes to 
Rac1 inhibition during adhesion maturation. It seems likely that all of these 
mechanisms may synergize to confine Rac1 activity and membrane protrusion to the 
leading edge of migrating cells and away from regions of high mechanical tension 
and RhoA/ROCK activity. As a consequence of the competitive binding to RhoGDI, 
increasing the binding affinity of one Rho protein leads to the release and 
degradation and/or activation of other Rho proteins (137). Interestingly, actomyosin 
contractility induces GDI dissociation from cell-matrix adhesions (114). However, the 
mechanism of GDI recruitment to adhesions is not known. 
Experimentally manipulating force 
Before considering some of ways that force can be applied to cells, it is useful 
to consider some of the forces that cells can exert and experience. The force exerted 
by a single myosin motor is between 1 and 8 pN (138-140). (1 Newton = 105 dynes. 
Dynes were used for many of the more classical measurements of force, but today 
Newtons are the unit of force generally used.) The maximum tension developed by 
striated muscle has been calculated to be ~ 3 × 106 dynes/cm2 (= ~300 nN/μm2), 
which translates to ~3 × 10−5 dynes per thin filament (i.e. ~300 pN per thin filament) 
(141). For cells in culture, various forms of traction force microscopy have been used 
to measure the tension that they generate on their adhesions and the substratum. 
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Here we will consider just a few of the values that have been obtained. In some of 
the first experiments investigating the force generated on the substratum by cultured 
cells, Harris and colleagues calculated an approximate value of 10 nN per μm of cell 
length (81). Lee and coworkers concluded that the maximum force generated by fish 
keratocytes was ~20 nN (142). Using a cantilever device, Galbraith and Sheetz 
obtained a force of 0.2 to 4 nN/μm2 for migrating fibroblasts (143). Geiger’s lab 
examined the tension developed by focal adhesions and found that the stress was 
proportional to the size of the focal adhesion with a value of about 5.5 nN/μm2 (144, 
145). In general, the area of a focal adhesion relates to the diameter of the stress 
fiber attached to it. Consequently, because the number of force- generating myosin 
molecules will relate to the diameter of a stress fiber, intuitively one might expect 
there to be a constant ratio between the size of a focal adhesion and the force that is 
being transmitted through it to the substratum. However, an unexpected discovery 
was made by Beningo et al. who found that in migrating cells, more force was 
transmitted to the substratum by small nascent adhesions at the leading edge of 
cells than in larger more mature focal adhesions behind the leading edge (146). A 
possible resolution to the apparent discrepancy between these two sets of results 
comes from the work of Chen’s lab, who have studied traction generated by cells 
plated on deformable micro-posts (micro-needles) (147). Like the Geiger lab they 
found that for most adhesions there was a correlation between the size of a focal 
adhesion and the stress exerted at the adhesion. Indeed, they found a similar value 
of ~4–5 nN/μm2. However, in their work they also found a subset of smaller 
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adhesions less that 1 μm2 that generated high levels of stress that did not correlate 
with the size of the adhesion (147). These latter adhesions most likely relate to the 
adhesions studied by Beningo et al. at the leading edge of migrating cells (146). 
 Manipulations of the ECM and flexible substrata can be used to mimic the 
tensional forces cells experience in the body. Simply plating cells on more rigid 
rather than on more compliant substrata increases the tension generated by cells on 
their underlying matrix due to increased RhoA activity (see discussion below) (148). 
Various devices have been developed that allow investigators to stretch cells by 
stretching the substratum to which the cells are adhering. The development of 
culture dishes with a flexible base that can be stretched by applying a vacuum 
facilitated subjecting cells to periods of cyclic stretch (149, 150). The period of the 
stretch as well as the degree of stretch imposed on cells can be readily varied and a 
large literature now exists describing many signaling pathways that become 
activated in response to cyclic stretch. Tension has also been applied to individual 
cellsusing glass rods or needles (83, 151). With these it is often more difficult to 
know the precise force that is being applied to cells, although the amount of force 
required to bend a needle by a certain angle can be determined experimentally. 
Stretching or deforming a cell via a flexible substratum or by a glass rod or 
needle simultaneously affects many properties, including cell shape, the 
cytoskeleton, as well as a cell’s adhesion to the matrix and/or its neighbors. In order 
to examine the effects of tension on specific adhesion molecules different 
approaches have been developed taking advantage of optical (laser) tweezers or 
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magnetic tweezers to exert forces on beads that are attached to cells via specific 
ligands or antibodies. Wang and colleagues used ferromagnetic beads that were 
attached to cells via integrin ligands (152). The beads were magnetized in one 
direction and then a second magnetic field was applied at 90° inducing the beads to 
twist and exert a shear force. This allowed them to show that there was a stiffening 
response as force was applied and that this depended on the cytoskeleton (152). 
Sheetz’s group used optical tweezers to manipulate beads similarly coated with 
integrin ligands or antibodies(153). They used the optical tweezers to restrain 
individual beads against the force exerted by the cell. It was observed that cells 
sensed the restraining force and strengthened the cytoskeletal linkages to oppose 
this. One advantage of optical tweezers is that beads can be individually 
manipulated with great precision, allowing them to be placed at different points on a 
cell’s surface and to be moved in different directions. Optical tweezers can generate 
forces up to about 500 pN, but in the higher range of forces heat generated by the 
laser can be detrimental and limit the use of this approach. Whereas an advantage is 
the ease of examining single cell responses, optical tweezers are not suitable for 
bulk biochemical analyses of signaling pathways. 
Ingber and his group used an electromagnetic microneedle to apply force on 
magnetic beads coated with adhesion molecule ligands or antibodies (154, 155). 
With this system it is easy to apply predetermined pulses of force on beads by 
turning the current on for defined periods. The time between the magnet being on 
can also be varied so that the behavior of cells responding to the cessation of force 
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can also be examined. The magnitude of the force generated by magnetic tweezers 
can be easily varied by altering the magnetic field and bead size, resulting in forces 
ranging from 1 pN to 100 nN (154). This wide range of force that can be generated is 
a potential advantage of the technique. However, the application of force is 
unidirectional and the position of the beads relative to the cell surface is essentially 
random, reflecting where the beads have dropped. However, a significant advantage 
of using magnetic beads to generate force on cells is that tension can be applied to 
all the cells in a dish provided that sufficient beads are added and a permanent 
magnet is used (156). This facilitates biochemical analysis of signaling pathways 
induced by sustained force (101, 157). The forces generated on cells using magnetic 
beads and permanent magnets have been discussed in detail elsewhere (156, 158). 
As an example, studying the application of collagen- coated 3 μm magnetic beads to 
fibroblasts growing in a 60 mm dish and using a permanent ceramic magnet 2 cm 
above the dish, Zhao et al. calculated that they exerted 480 pN per cell or 0.65 
pN/μm2 (157). 
A large body of work has examined the effects of flow and shear force 
particularly on ECs. Because of their location lining blood vessels, these are 
exposed and respond to blood flow throughout their existence. Hemodynamic forces 
vary over a wide range within the vasculature, but most work has focused on the 
arterial system because the high flow within arteries is critical not only to their normal 
physiology but also is a major factor in the pathological development of 
atherosclerosis. ECs experience force perpendicular to the endothelium as a result 
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of blood pressure and force parallel to the blood vessel wall as a result of flow. The 
frictional force of blood flow generates shear stress that acts at the surface of ECs 
(159). This has pronounced effects on endothelial behavior (88, 90, 159-161). 
Straight regions of arteries result in laminar flow but this becomes disturbed when a 
vessel curves, bifurcates or branches. The mean wall shear stress of large arteries 
has been determined to be between 20 and 40 dynes/cm2 (159, 162), but much 
higher values (exceeding 100 dynes/cm2) have been recorded transiently at the 
peak of pulsatile flow resulting from the heart beat (163). Turbulent flow results in 
shear stress experienced by the endothelium that has been calculated to vary from 
negative values through zero to levels of between 40 to 50 dynes/cm2 (163). Several 
devices have been developed to allow the effects of flow and shear stress to be 
examined on cells in culture. These include the cone plate viscometer, in which flow 
is generated by the rotation of a cone above cells growing in a culture dish (164, 
165). The shear stress and whether flow is laminar or turbulent are determined by 
the angle of the cone, the viscosity of the medium and speed of rotation. Parallel 
plate flow chambers are frequently used to study the effects of flow on cells. In 
these, fluid is pumped between two glass sheets, on one of which the cells of 
interest have been cultured (166, 167). Cells can also be grown in capillary tubes 
through which fluid is similarly pumped at levels determined by the investigator to 
mimic the desired shear forces (168, 169). With both parallel plate chambers and 
capillary tubes, turbulent flow can be generated by reversing the direction of flow or 
by stopping and starting flow. Shear stress values can be generated that cover the 
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full range experienced by arterial ECs in vivo (159, 162). 
Not only can exogenously applied force be experimentally modulated, but the 
endogenous forces generated by actomyosin contractility within cells can also be 
controlled by the investigator. This can be achieved by directly affecting myosin 
activity or by modifying upstream signaling pathways. Myosin ATPase activity can be 
inhibited by the drug blebbistatin, which has become a valuable tool for cell 
biologists interested in decreasing endogenous tension (170). The major limitation 
using this drug is that it is photo-sensitive and therefore cannot easily be used with 
live cell imaging. Alternatively, the expression of myosin II isoforms (usually myosin 
IIA or IIB) can be knocked down using siRNA techniques. Given the key role of RhoA 
and ROCK in regulating myosin activity in cells, contractility is often manipulated by 
inhibiting the RhoA/ROCK signaling pathway. Direct inhibition of RhoA is achieved 
using treatment with the Botulinum exotransferase C3 which ADP-ribosylates RhoA. 
Several ROCK inhibitors have been developed, but the most frequently used 
experimentally is Y27632 (171)(95). The disadvantage of perturbing the RhoA/ 
ROCK pathway is that contractility is only one of many downstream signaling events 
that is affected, often making interpretation of results difficult. Stimulating contractility 
can be induced in several ways. Expression of constitutively active RhoA drives 
activation of the ROCK pathway and elevates myosin activity, but again there will be 
many other effects. The level of MLC phosphorylation can also be enhanced by 
inhibiting phosphatase activity pharmacologically, for example with calyculin A. This 
potently stimulates contractility (172), but here too there will be many side effects. 
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The phosphorylation state of the regulatory MLC can also be mimicked by 
expression of mutant MLCs in which one or both of the critical phosphorylatable 
residues (threonine18 and serine19) are mutated to aspartic acid. These generate 
constitutively active forms and have been used in several studies (see for example 
(173)). The difficulty with these mutants is that the dynamic nature of regulation by 
phosphorylation is blocked because the myosin molecules are locked into a single 
activated state. 
Rigid substrata, stress fibers and focal adhesions 
On substrata of different compliance, cells exhibit strikingly different 
behaviors. Compared with when they are cultured on more rigid surfaces, on more 
compliant substrates fibroblasts are less able to develop stress fibers and focal 
adhesions but migrate more rapidly (174). Culturing cells on substrates of different 
compliance can also have profound effects on gene expression (175, 176). The 
behavior of cells on relatively soft substrata relates to the general observation that in 
tissue culture many cells develop stress fibers and focal adhesions, although the 
same cells within their host tissues rarely develop these structures (177). What is it 
about tissue culture and rigid substrata that promote the formation of these 
structures that often dominate a cell’s cytoskeletal appearance? In tissue culture, 
frequently one factor is the presence of agents in serum such as LPA and S1P that 
activate RhoA (34). These derive from platelet secretions during blood clot 
formation. In wound healing they probably contribute to the contraction of cells 
surrounding a wound site. Notably, tissue culture has often been likened to a wound 
  30 
response. However, even in the absence of serum and these factors, many 
fibroblasts develop stress fibers and focal adhesions when plated on rigid substrata 
coated with matrix proteins. Conversely, even in the presence of serum, cells 
adhering to soft substrata are unable to assemble these structures (174). The rigidity 
of the substratum is a second factor contributing to the development of focal 
adhesions and stress fibers. On rigid substrata cells such as fibroblasts generate 
strong tractional forces to the matrix components adsorbed to the surface of the 
culture dish or cover glass. The resulting isometric tension was suggested many 
years ago as a factor in the development of these structures (97). Subsequent work 
has shown that culturing cells on rigid surfaces elevates RhoA activity (178, 179). 
The importance of tension in the development of these structures is supported by a 
large body of evidence, including numerous experiments showing that inhibiting the 
RhoA/ROCK pathway or myosin activity blocks the development of stress fibers and 
focal adhesions, and leads to the disassembly of these structures if they have 
already formed (34, 93, 180-182). The development of stress fibers and focal 
adhesions on rigid substrata is the quintessential example of endogenously 
generated tension affecting the organization of the cytoskeleton and cell behavior. 
Synergy between endogenously generated tension and tension applied exogenously 
promoting the assembly of these structures was elegantly demonstrated by Riveline 
and coworkers who showed that applying tension on cells adhering to rigid substrata 
promoted the growth of focal adhesions (151). 
In addition to endogenous tension contributing to the assembly of focal 
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adhesions and stress fibers, a major contribution to the activation of RhoA derives 
from integrin engagement with the ECM. This is a complex biphasic response, in 
which integrin-mediated adhesion initially depresses and then elevates RhoA activity 
(126, 183). The RhoA GEFs, p115/Lsc, LARG and p190RhoGEF were all shown to 
be activated upon adhesion to fibronectin (102, 107). Both the engagement of 
integrins and the mechanical tension exerted on these adhesion molecules leads to 
the activation of RhoA (101, 102, 107). 
ECM Compliance and gene expression 
It has been known for a long time that the differentiated phenotype of many 
cells is often lost when they are grown on rigid plastic substrates as opposed to 
being cultured on more appropriate ECM proteins. This is particularly true when the 
growth and differentiation characteristics of epithelial cells are compared between 
cultures growing on plastic or on ECM components that recapitulate many of the 
characteristics of basement membrane (184). Many studies revealed that the 
expression of differentiated genes depends not only on the presence of appropriate 
growth factors but also on an appropriate ECM. For example, the morphology and 
gene expression exhibited by breast epithelial cells were profoundly influenced not 
only by the composition of the matrix but also its physical state. Thus it was shown 
early on that culturing breast epithelial cells on floating collagen gels, which are 
compliant, compared with collagen gels anchored to rigid culture dishes affected the 
expression of specific genes (185). 
With hindsight, many of the effects of matrix rigidity or cell shape on the 
  32 
differentiated phenotype can be understood in the context of RhoA/ROCK signaling. 
Numerous studies have led to the conclusion that the level of RhoA activity affects 
differentiation and gene expression (88, 186, 187). For example, Sordella and 
coworkers studying the phenotype of the p190-B RhoGAP null mouse discovered 
that mice lacking this major negative regulator of RhoA activity, not only had 
elevated RhoA activity, but were defective in adipogenesis and had enhanced 
myogenesis. They concluded that there was a Rho-dependent switch that regulated 
stem cells to differentiate in a myoblast direction under conditions of high RhoA 
activity but to differentiate into adipocytes under low RhoA activity (188). This work 
was extended by others. For example, McBeath and colleagues using human 
mesenchymal stem cells (MSCs) in culture demonstrated that their commitment into 
osteoblasts or adipocytes was determined by their cell shape and that MSCs that 
flattened and spread became osteoblasts whereas the same cells prevented from 
spreading became adipocytes (189). These investigators found that inhibiting the 
RhoA pathway drove the MSCs toward the adipocyte pathway, but activating RhoA 
induced the osteoblast lineage. They went on to show that this latter pathway was 
mediated by the RhoA effector, ROCK, and that expression of activated ROCK was 
sufficient to drive osteogenesis. Interestingly, this occurred even when the cells were 
kept in a rounded state, whereas expressing activated RhoA was not sufficient to 
overcome the inhibitory effect of cell rounding on osteogenesis. These results 
suggested that the link between RhoA and ROCK could be uncoupled by cell 
rounding. Pursuing this further, Chen’s group showed that indeed in rounded cells 
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there was high RhoA activity but low ROCK activity and that the level of myosin light 
chain phosphorylation was similarly low. Additionally, they found that inhibiting 
endogenous cell tension either by disrupting the cytoskeleton with cytochalasin or by 
blocking myosin with blebbistatin also inhibited ROCK activity, although in the case 
of cytochalasin treatment this decrease in ROCK activity occurred in the presence of 
high RhoA activity (182). Their results suggested a positive feedback mechanism by 
which mechanical tension is needed to maintain high ROCK activity. In terms of the 
uncoupling between ROCK and RhoA activities, tyrosine phosphorylation of ROCK2 
was shown to inhibit its activation by RhoA (190). This tyrosine phosphorylation was 
found to occur in response to adhesion and likely allows RhoA signaling to activate 
mDia but not ROCK, such that actin polymerization and cell spreading are promoted 
but contraction is inhibited. The high activity of RhoA that has been detected at the 
leading edge of migrating cells (191) has been difficult to explain in terms of models 
where RhoA drives contractility but can be easily accommodated in models where 
there is a regulatory bifurcation downstream from RhoA such that ROCK is inhibited 
while mDia is activated. However, in the case of cell rounding leading to ROCK 
inhibition, we suspect that this may involve other pathways because cell rounding is 
usually associated with decreased levels of tyrosine phosphorylation for many 
proteins (192). 
In a detailed study in which MSCs were cultured on matrices that closely 
related to the compliance of their endogenous tissue environments, it was shown 
that soft substrata resembling the stiffness of brain induced a neurogenic pattern of 
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gene expression, whereas on stiffer substrata mimicking muscle the same cells were 
myogenic, and on the stiffest matrices resembling collagenous bone the cells were 
osteogenic (176). Significantly, it was found that blocking myosin II activity inhibited 
the effects of matrix compliance on the resulting phenotype providing further support 
for the importance of myosin and tension in the sensing of matrix rigidity. Exploring 
how transcription may be regulated by matrix rigidity, cytoskeletal tension and RhoA 
activity, Piccolo’s group examined the transcriptional profiles of several cell types on 
substrates of differing compliance and identified the YAP/TAZ transcriptional 
regulators as key factors in controlling the enhanced expression of specific genes on 
more rigid substrates (193). Specifically, the distribution of these factors in the 
nucleus or in the cytoplasm was found to be determined by rigid versus soft 
matrices, respectively. Inhibiting RhoA, ROCK or myosin II activity was found to 
keep YAP and TAZ in the cytoplasm, whereas active RhoA drove them into the 
nucleus and induced the expression of genes associated with rigid matrices. It will 
be interesting in the future to learn how this is accomplished, but together with many 
of the studies mentioned above this work establishes a pathway by which a cell 
responds to the rigidity or compliance of its environment and alters its pattern of 
gene expression accordingly. 
Tension at Cell-Cell junctions 
The role of RhoA activity and mechanical tension in cell-cell junctions is 
complex. Numerous studies with agents that increase endothelial permeability, such 
as thrombin, have implicated both increased RhoA activity and myosin-based 
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contractility with opening of endothelial junctions and increased permeability (194, 
195). However, other work has indicated a role for RhoA in junction assembly(121, 
196-199). Not only is RhoA activity required for junction assembly, but several 
studies have shown that myosin-induced tension downstream from RhoA can 
promote junction assembly (118, 200-202). These results appear at first sight to be 
contradictory. We suspect that under conditions where tension is associated with 
junctional disruption other factors must contribute to weakening the junctions. 
Support for this idea comes, for example, from studies of HIV-induced encephalitis in 
which there is increased monocyte passage across the blood/brain barrier and 
disruption of endothelial tight junctions. The weakening of tight junctions was related 
to ROCK-mediated phosphorylation of two tight junction proteins, occludin and 
claudin-5 (203). It seems likely that many agents that increase permeability and 
open cell-cell junctions simultaneously increase tension while weakening the 
adhesive strength of the junctional CAMs. On the other hand in situations where 
RhoA and increased contractility enhance junction assembly, we assume that the 
signals must segregate such that the junctional CAMs maintain their adhesive 
strength or increase it so that increased tension does not break the adhesions and 
open gaps between the cells. With respect to the strengthening of junctions in 
response to mechanical force, it was discovered that α-catenin changes its 
conformation in response to tension on epithelial junctions to expose a cryptic site 
that can bind vinculin (121, 202). In parallel work, it was shown that vinculin is 
recruited to adherens junctions in response to mechanical tension and that tension 
  36 
on E-cadherin leads to a stiffening response that is dependent on vinculin (120). 
Together these studies support a model in which RhoA-mediated tension on cell-cell 
junctions can have opposite effects depending on the adhesive strength of the 
junctional CAMs and their associated protein complexes. 
Cadherin engagement has been found to either decrease (204, 205) or 
increase RhoA activity (206-208). Differences in these results may reflect in part the 
different signaling pathways initiated downstream from different cadherins. However, 
some of the differences may be due to the presence or absence of force on the 
cadherins. Working with ECs and VE-cadherin, Nelson and colleagues observed that 
sustained adhesion via VE- cadherin resulted in a peak of RhoA activity 6 hours 
following VE-cadherin engagement and they provided evidence that this was 
dependent on tension being transmitted to the sites of cell-cell adhesion. In contrast, 
the depression in RhoA activity upon E-cadherin engagement was rapid (204). 
Consistent with the idea that mechanical force on the cadherin may switch the 
signaling pathway from depressing RhoA activity to elevating it, we have found that 
while simple engagement of E-cadherin leads to decreased RhoA activity, applying 
force to the cadherins elevates RhoA activity (Marjoram and Guilluy, unpublished 
results). It will be interesting to identify the GEFs that become activated in response 
to tension on E-cadherin. 
In many situations mechanical force on cells is associated with increased 
proliferation. Investigating the role of cell-cell adhesions versus cell-matrix adhesions 
in mechanical signaling to induce cell proliferation, Chen’s group compared the 
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response of ECs and vascular smooth muscle cells to mechanical force (209). 
Subjecting both cell types to stretching stimulated proliferation but ECs required cell-
cell adhesion and engagement of VE-cadherin for proliferation to occur, whereas 
smooth muscle cells responded to stretch by proliferation in the absence of cell-cell 
contact. Interestingly, the authors found that stretching ECs activated Rac1 and this 
was required for proliferation. However, upon stretching smooth muscle cells RhoA 
activation was needed for proliferation (209). This result is in contrast to the absence 
of RhoA activation found by Schwartz’ group when smooth muscle cells were 
stretched, but differing conditions probably account for the apparent discrepancy 
(210). 
Cancer 
During development, the rigidity/compliance of different regions of embryos is 
thought to have a major impact on the differentiation and organization of various 
tissues and organs. This view is supported by the large body of work studying cells 
grown in culture that indicates the importance of the physical characteristics as well 
as the composition of the microenvironment. There are also disease situations 
where the rigidity of tissues alters and affects cell behavior. Examples include many 
solid tumors, the hardening of arterial walls that occurs with age, atherosclerosis, 
and fibrotic diseases where there is increased deposition of ECM. Solid tumors are 
often detected by physical palpation, an indication that they are less compliant than 
the surrounding tissues. The increased rigidity of tumors not surprisingly has been 
associated with increased RhoA activity and other altered signaling pathways (179)
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Many epithelial cell types adopt a more normal morphology and phenotype when 
grown in relatively soft 3D matrices and this is lost when the same cells are cultured 
on rigid two dimensional surfaces (211). Working with breast epithelial cells in 
culture, it was found that changing the compliance of the ECM alone promoted a 
more malignant cancer phenotype (179). Cells grown on a stiff matrix exhibited 
larger colony size, increased ERK activity, elevated RhoA activity, more focal 
adhesions, and greater tractional force applied to the ECM compared to cells grown 
on a soft ECM. Blocking ROCK activity caused the cells on the stiff ECM to behave 
more like cells grown on a compliant ECM. Elevated RhoA-dependent signaling 
disrupted the normal epithelial morphology of the breast epithelial cells, which in soft 
matrices grow as spheroids with a cell polarity mimicking that found in the normal 
gland. On more rigid substrata the cells lost their polarized organization and the cell 
aggregates failed to develop lumens. These changes are reminiscent of the changes 
associated with malignancy (179, 212). Elevated rigidity has been shown to have 
protumorigenic effects in other cell types as well. For example, expression of 
activated forms of ROCK2 in skin resulted in increased stiffening associated with 
increased collagen deposition (213). This was associated with nuclear accumulation 
of β-catenin, transcriptional activation and hyperproliferation. Interestingly, when 
human skin squamous cell carcinomas were examined, the majority were found to 
have elevated ROCK expression and activity (213). 
Mechanical tension in tumors is associated not only with increased cell 
proliferation but also with enhanced invasion (214). Tumor cells migrate along 
  39 
aligned collagen fibrils and this is promoted by increased mechanical tension within 
the tumor (215). When tumor cells move in tissues either they migrate as cell 
collectives where a group of cells migrate together while maintaining their cell-cell 
contacts or they migrate as individual cells (216). In the latter situation they have 
been found to migrate in two distinct ways, which have been described as 
mesenchymal versus amoeboid or rounded (217, 218). These two types of migration 
appear to be interchangeable and the mesenchymal form can be driven to become 
the amoeboid type by inhibiting proteases involved in degrading the ECM or by 
elevating RhoA and ROCK activity. Conversely, the mesenchymal mode of migration 
is promoted by high Rac1 but low RhoA activity (136, 216).  
Future directions 
The discovery that mechanical forces exerted exogenously on cells or 
generated endogenously within them leads to Rho protein activation and signaling 
has many implications. This pathway is important in development, preferentially 
driving stem cell differentiation along one lineage versus another. With the 
increasing interest in potential stem cell therapies, recognition of the impact of the 
physical properties of the environment is important. However, knowing that these 
effects of the environment are driven by the RhoA/ ROCK pathway should permit 
these environmental influences to be overridden by manipulating this signaling 
pathway so as to direct the differentiation of stem cells along predetermined lines. 
Elucidating the signaling pathways from mechanical force to Rho protein activation 
may also impact the approach to various pathologies such as fibrosis and cancer. 
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However, with tumors there is a red flag in that tumor cells can switch their mode of 
migration from a mesenchymal type to an amoeboid type according to the relative 
activities of Rac1 and RhoA. Consequently, the tempting idea that decreasing tumor 
cell RhoA activity may be beneficial, leading to decreased cell proliferation and 
favoring a more normal phenotype, may have unexpected consequences converting 
invasive tumor cells from one migratory phenotype to another. Nevertheless, when 
combined with other therapies, such as inhibiting Rac1-driven migration, targeting 
RhoA activity in tumors may be advantageous. The identification of upstream 
signaling components such as GEFs promises to provide novel targets for 
therapeutic development, not only for certain cancers but also for other disease 
where mechanosensitive signaling may be involved. 
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Chapter 3: THE RHOA GUANINE NUCLEOTIDE EXCHANGE FACTOR, LARG, 
MEDIATES ICAM-1-DEPENDENT MECHANOTRANSDUCTION IN ENDOTHELIAL 
CELLS TO STIMULATE TRANSENDOTHELIAL MIGRATION2 
 
Introduction 
Leukocyte extravasation is a tightly controlled process that involves signaling 
in both the leukocyte and EC. Neutrophils are early responders to sites of infection. 
Pro-inflammatory signals prompt them to exit post-capillary venules and infiltrate 
tissues to ingest microbes or foreign bodies, destroying them with proteolytic 
enzymes and/or the release of reactive oxygen species. In response to inflammatory 
signals, several adhesion molecules become expressed or increased on the EC 
surface including ICAM-1. Leukocyte TEM starts with leukocyte rolling, mediated by 
leukocyte binding to selectins on the surface of ECs (219). β2 integrins on the 
leukocyte then bind to ICAM-1 (13-21). The strong adhesion resulting from ICAM-1 
                                            
 
2 The citation is as follows: Lessey-Morillon, E. C., Osborne, O., Monaghan-Benson, 
E., Guilluy. G., O’Brien, T. E., Superfine. R., Burridge, K., (2014) The RhoA guanine 
nucleotide exchange factor, LARG, mediates ICAM-1-dependent 
mechanotransduction in endothelial cells to stimulate transendothelial migration. 
Journal of Immunology. 
http://www.jimmunol.org/content/early/2014/02/28/jimmunol.1302525 
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engagement and clustering allows leukocytes to spread and crawl on the surface of 
the endothelium. Finally, leukocytes cross the EC monolayer, either passing through 
the junctions or through the ECs themselves (20, 30, 220) to enter the underlying 
tissue. Without ICAM-1, leukocyte spreading, crawling and TEM are impaired (57, 
59).  
 Engagement and clustering of ICAM-1 by leukocytes induces multiple 
signaling pathways within ECs (22) that promote passage of the leukocytes across 
the endothelium. After ICAM-1 clustering, F-actin and actin binding 
proteins associate with the clustered complex to assist in the cytoskeletal changes 
that occur during leukocyte adhesion and TEM (21, 31, 61-64). One of the pathways 
responsible for these changes involves the GTPase RhoA, which was shown to be 
activated following ICAM-1 engagement and clustering (16, 31). Inhibiting RhoA 
signaling in ECs reduces leukocyte adhesion, spreading, and migration (14, 15, 59, 
60). RhoA is also activated by various agents, such as thrombin, that increase the 
permeability of EC junctions (49, 221, 222). In part, this is due to RhoA-stimulated 
actomyosin contraction that exerts tension on the junctions, however, there is 
additional evidence that the adhesive strength of the junctions is weakened by 
signaling downstream of active RhoA (203). Clustering of ICAM-1 also elevates 
tyrosine phosphorylation of multiple proteins and several studies have identified Src 
family kinases (SFKs) as being responsible and being activated downstream of 
ICAM-1 (64, 65, 223, 224). However, the relationship between SFK activity and Rho 
protein activation downstream from ICAM-1 has not been explored. 
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Cell migration requires the cell to exert tractional forces on the underlying 
substratum. The amount of traction force generated by migrating leukocytes has 
been estimated to be between 5 and 50 pN (225-227). It is unclear if EC signaling is 
altered in response to the tractional force applied by leukocytes to adhesion 
molecules expressed on the EC luminal surface. At the outset of this work, we were 
interested in determining whether the tractional forces exerted on ICAM-1 as 
leukocytes migrate affect RhoA signaling, and secondly, we were interested in 
identifying GEFs that activate RhoA downstream of ICAM-1. Here we identify LARG, 
also known as ARHGEF12, as the critical RhoA GEF activating RhoA downstream of 
ICAM-1, show that it is activated by SFK-dependent tyrosine phosphorylation, and 
demonstrate that applying mechanical force on ICAM-1 clusters equivalent to the 
forces generated by migrating neutrophils enhances this signaling pathway. We 
provide evidence that this activation of RhoA not only promotes neutrophil TEM but 
stiffens the endothelial surface thereby enhancing the migration of neutrophils over 
it.  
Results  
Mechanical force on ICAM-1 increases cellular stiffness around ICAM-1 clusters. 
We first sought to determine if mechanical force on ICAM-1 induces a cellular 
response. We used beads coated with aICAM-1 mAb as a model to mimic leukocyte-
induced ICAM-1 clustering (30). The beads were also magnetic, allowing us to apply 
force on the ICAM-1 clusters. To assess cellular stiffness, we measured 
displacement of attached beads during pulses of force (101, 155, 228). We applied 
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pulses of 160 pN force on ICAM-1 and tracked the bead location during each pull 
(Figure 7A). There was no statistically significant difference in the initial average 
displacements of the beads on cells grown on collagen (0.5 µm) or fibronectin (0.4 
µm). We observed that after the first pulse of force subsequent pulses did not 
displace the beads as much, indicating cellular stiffening (Figure 7B). This stiffening  
response occurred whether the ECs had been cultured on a fibronectin or collagen 
ECM, revealing that the response was not affected by the integrins through which 
the ECs were adhering to the matrix (Figure 7B,C). Since there was little change in 
bead displacement between the second pulse and subsequent pulses, for most 
experiments we have compared the bead displacement generated by the first and 
second pulse. 
To explore the basis for the force-induced stiffening, we examined the effects 
of agents that perturb the cytoskeleton. The average initial bead displacement for 
control cells, and cells treated with blebbistatin, cytochalasin D, Y-27632 and 
SU6656 were 0.4, 0.6, 0.8, 0.4, and 0.6 µm, respectively. The stiffening response 
was blocked by disrupting the actin cytoskeleton with cytochalasin D or by inhibiting  
myosin activity with blebbistatin (Figure 7D). To inhibit the RhoA/ROCK pathway we 
used the ROCK inhibitor Y-27632 (Figure 7D) and used adenoviral delivery ofmiRNA 
to knockdown RhoA expression (Figure 7E, F). We found that knockdown of RhoA 
as well as inhibition of ROCK both inhibited the force-induced stiffening response. 
The SFK inhibitor, SU6656, also was able to prevent any change in bead 
displacement between pulses (Figure 7D). Taken together these results suggest that 
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Figure	  7:	  Mechanical	  force	  on	  ICAM-­‐1	  increases	  cellular	  stiffening	  
Magnetic	  beads	  coated	  with	  ICAM-­‐1	  mAb	  were	  added	  to	  a	  monolayer	  of	  TNF-­‐treated	  HMVECs.	  Magnetic	  
tweezers	  were	  used	  to	  apply	  pulses	  of	  force	  to	  individual	  beads	  and	  bead	  movement	  recorded	  with	  high-­‐
speed	  video.	  (A)	  Typical	  displacement	  of	  a	  bead	  bound	  to	  ICAM-­‐1.	  Arrows	  denote	  displacement	  distance	  
(Top).	  A	  diagram	  of	  the	  160	  pN	  force	  regimen	  used	  (3s	  of	  force	  with	  5s	  recovery	  for	  5	  pulses)	  (Lower).	  
Percentage	  bead	  displacement	  in	  response	  to	  sequential	  pulses	  of	  force	  for	  ECs	  plated	  on	  collagen	  (B)	  or	  
fibronectin	  (C).	  For	  D-­‐F,	  the	  ECs	  were	  plated	  on	  collagen.	  (D)	  Bead	  displacements	  on	  HMVECs	  treated	  with	  
specified	  inhibitors	  for	  30	  min	  followed	  by	  2	  pulses	  of	  force.	  (E)	  Bead	  displacement	  on	  HMVECs	  and	  HMVECs	  
treated	  with	  miRNA	  to	  inhibit	  RhoA	  expression	  with	  or	  without	  rescue	  with	  myc-­‐RhoA.	  (F)	  Western	  blotting	  
confirms	  RhoA	  knockdown	  and	  myc-­‐RhoA	  re-­‐expression.	  (B-­‐E)	  Quantification	  of	  bead	  displacement	  with	  
each	  pulse	  normalized	  to	  the	  first	  pulse.	  Asterisks	  shows	  p-­‐value	  of	  statistical	  significance	  compared	  to	  the	  
control	  (*,	  p≤0.05;	  **,	  p≤0.01).	  The	  means	  ±	  SEM	  of	  ≥9	  independent	  bead	  pulls	  are	  shown.	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ECs respond to mechanical force on ICAM-1 and the observed stiffening response is 
dependent on the actin cytoskeleton, myosin activity, RhoA signaling and SFK 
activity.  
RhoA is activated by mechanical force on ICAM-1 
After we had determined that the cellular stiffening was dependent on RhoA 
expression and actomyosin contractility we next wanted to examine RhoA activity 
levels. A considerable body of work has revealed the importance of RhoA within ECs 
in facilitating the passage of leukocytes across the endothelium (15, 16, 31, 57). To 
cluster ICAM-1, we incubated cells for 15 min with magnetic beads coated with 
aICAM-1 mAb, and then applied force with a permanent magnet placed above the 
cell culture dish for 1 min to provide ~10 pN of force  (Figure 8A). Consistent with 
previous findings (14, 15, 31), ICAM-1 clustering increased RhoA activity over 
untreated cells (Figure 8A). RhoA activity was further increased within 1 min of 
mechanical force on the ICAM-1 bead clusters (Figure 8A). To evaluate if the 
observed activation of RhoA was specific to ICAM-1, we clustered and applied force 
on MHC class I. Neither clustering, nor force application on MHC class I significantly 
affected RhoA activity (Figure 8B), confirming that the activation of RhoA is not a 
universal response to tension on the cell surface. Both MHC class I beads and the 
ICAM-1 mAb coated beads were able to bind to the EC monolayer as seen by phase 
contrast microscopy (Figure 8C). MLC phosphorylation is frequently elevated 
downstream from RhoA activation and this was observed paralleling the increase in 
RhoA activity as ICAM-1 was clustered and then subjected to force (Figure 8D). 
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Figure	  8:	  Mechanical	  force	  on	  ICAM-­‐1	  increases	  RhoA	  activity	  and	  MLC	  phosphorylation	  
Magnetic	  beads	  coated	  with	  mAb	  against	  ICAM-­‐1	  (A,	  C,	  and	  D)	  or	  MHC	  class	  I	  (B	  and	  C)	  were	  added	  for	  15	  
min	  to	  a	  monolayer	  of	  TNF-­‐treated	  HUVECs	  and	  ~10	  pN	  force	  was	  applied	  with	  a	  ceramic	  magnet	  placed	  
above	  the	  cells	  for	  1	  min.	  (A	  and	  B)	  Using	  GST-­‐RBD,	  RhoA.GTP	  was	  isolated	  and	  detected	  by	  immunoblotting.	  
(C)	  Phase	  contrast	  images	  of	  EC	  monolayers	  15’	  after	  beads	  were	  added	  and	  washed	  2x	  with	  media	  before	  
fixing.	  (D)	  Lysates	  were	  immunoblotted	  for	  total	  MLC	  or	  MLC	  phosphorylated	  on	  Thr18/Ser19.	  Graphs	  show	  
quantification	  of	  RhoA	  activity	  (A	  and	  B)	  or	  pMLC	  levels	  (D)	  from	  ≥3	  independent	  experiments.	  Graphs	  show	  
the	  means	  ±	  SEM.	  Asterisk	  shows	  p-­‐value	  of	  statistical	  significance	  compared	  to	  control	  (*,	  p≤0.05;	  **,	  
p≤0.01).	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ICAM-1 signaling activates LARG 
While a downstream role for RhoA activity after ICAM-1 engagement has long 
been established, the GEF mediating activation of RhoA has not been determined. 
Using the binding of GEFs to nucleotide-free mutant RhoAG17A as an indicator of 
GEF activation (229), we tested several candidate GEFs including LARG, 
p190RhoGEF p115RhoGEF, G-H1 and PDZ-RhoGEF, but only observed activation 
of LARG in response to ICAM-1 clustering (Figure 9A-E). There was an additional 
increase in LARG activity when force was applied to the clustered ICAM-1 (Figure 
9A).  Neither clustering MHC class I, nor applying tension on this receptor affected 
LARG activity (Figure 9F). ICAM-1 clustering induced LARG tyrosine 
phosphorylation and application of force on ICAM-1 further elevated this 
phosphorylation (Figure 9G). Treatment of cells with the SFK inhibitor, SU6656, 
inhibited LARG activation induced by ICAM-1 clustering and greatly attenuated 
LARG activation after ICAM-1 clustering with force (Figure 9H). These results 
strongly suggest a pathway in which clustering of ICAM-1 activates SFKs (64, 65, 
223, 224) to phosphorylate and activate LARG.  
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Figure	  9:	  LARG	  is	  activated	  downstream	  of	  ICAM-­‐1	  clustering	  alone	  and	  enhanced	  with	  mechanical	  
force	  
TNF-­‐treated	  HUVECs	  were	  treated	  with	  mAb-­‐coated	  beads.	  (A-­‐F)	  GEF	  activity	  was	  determined	  by	  affinity	  
purification	  via	  GST-­‐RhoAG17A	  and	  detected	  by	  immunoblotting	  for	  the	  specified	  GEF,	  LARG	  (A	  and	  F),	  
p190RhoGEF	  (B),	  p115	  (C),	  GEF-­‐H1	  (D),	  PDZ-­‐RhoGEF	  (E).	  (G)	  LARG	  was	  immunoprecipitated	  and	  
immunoblotted	  for	  phosphotyrosine	  and	  LARG.	  (H)	  Active	  LARG	  was	  detected	  by	  sedimentation	  with	  GST-­‐
RhoAG17A	  in	  the	  presence	  of	  SU6656.	  For	  all	  experiments,	  a	  representative	  blot	  of	  ≥2	  independent	  
experiments	  is	  shown.	  Graphs	  show	  the	  means	  ±	  SEM.	  Asterisk	  shows	  p-­‐value	  of	  statistical	  significance	  
compared	  to	  control	  by	  t	  test	  (*,	  p≤0.05;	  **,	  p≤0.01).	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Knockdown of LARG expression inhibits RhoA activation downstream of ICAM-1 
clustering  
To further investigate whether LARG activation is responsible for the increase 
in RhoA activity downstream of ICAM-1 signaling, we used lenti-shRNA technology 
to depress LARG expression. ECs were infected with LARG shRNA or scrambled 
control shRNA. We confirmed by immunoblotting that LARG protein levels were 
reduced by the lenti-shRNA treatment and that the levels of similar GEFs like p115 
were not decreased (10A). Interestingly, p115RhoGEF showed a slight increase in 
expression in response to LARG knockdown. TNF induction of ICAM-1 expression 
was preserved with control and LARG shRNA treatment (10B). We also sought to 
confirm that LARG knockdown did not alter resting junctional permeability. This was 
examined by assaying electrical impedance (10C). After LARG knockdown there 
was no RhoA activation in response to ICAM-1 clustering or when force was applied 
to the ICAM-1 clusters (Figure 11A). The control shRNA-treated ECs exhibited 
ICAM-1-clustering and force-dependent RhoA activation similar to wild type ECs 
(Figure 11B).  
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10:	  Confirmation	  of	  LARG	  knockdown	  
HMVECs	  were	  treated	  with	  control	  or	  LARG	  shRNA	  lenti-­‐virus	  for	  48	  h	  and	  selected	  for	  with	  2.5	  ng/ml	  
puromycin	  for	  24	  h.	  (A)	  EC	  lysates	  were	  immunoblotted	  with	  the	  indicated	  pAb.	  (B)	  Western	  blotting	  shows	  
that	  ICAM-­‐1	  expression	  before	  and	  after	  TNF-­‐treatment	  is	  not	  affected	  by	  LARG	  knockdown.	  (C)	  Electrical	  
impedance	  was	  used	  to	  measure	  monolayer	  integrity	  for	  HMVECs	  plated	  at	  high	  density	  for	  72	  h.	  No	  
significant	  difference	  was	  found	  in	  impedance	  values	  after	  control	  or	  LARG	  knockdown.	  n=3	  independent	  
experiments	  preformed	  in	  triplicate	  wells.	  	  
 
To determine if LARG knockdown affected the cellular stiffness at ICAM-1 
clusters, we used magnetic tweezers as in Figure 7. We measured the stiffness of 
the cells with a single pulse of force on ICAM-1 (Figure 11C). The stiffness 
measured was 50 Pa in control cells compared to 37 Pa in LARG knockdown cells. 
While there was a reproducible trend of ECs becoming softer after LARG 
knockdown, this difference was not statistically significant. However, after LARG 
knockdown there was a loss of the adaptive stiffening at ICAM-1 clusters in 
response to force after the first pulse. Compared to the control knockdown ECs or 
untreated cells, LARG knockdown ECs revealed no change in bead displacement 
between the first and second pulse (Figure 11D).  
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Figure	  11:	  LARG	  mediates	  EC	  response	  to	  mechanical	  force	  on	  ICAM-­‐1	  and	  affects	  neutrophil	  
crawling	  and	  TEM	  
HUVECs	  were	  treated	  with	  control	  (B	  and	  C)	  or	  LARG	  (A	  and	  C)	  shRNA	  lenti-­‐virus	  for	  48	  h	  and	  selected	  with	  
2.5	  ng/ml	  puromycin	  for	  24	  h,	  then	  TNF-­‐treated	  overnight.	  (A	  and	  B)	  RhoA	  activity	  was	  determined	  by	  
immunoblotting	  after	  ICAM-­‐1	  clustering	  with	  or	  without	  force	  in	  HUVECs	  (left)	  and	  quantified	  (right).	  The	  
means	  ±	  SEM	  of	  ≥4	  independent	  experiments	  are	  shown.	  Asterisk	  shows	  p-­‐value	  of	  statistical	  significance	  by	  
t	  test	  (*,	  p≤0.05).	  (C)	  The	  stiffness	  of	  HMVECs	  was	  measured	  using	  magnetic	  tweezers	  and	  magnetic	  beads	  
coated	  with	  ICAM-­‐1	  mAb.	  (D)	  Relative	  displacement	  of	  magnetic	  beads	  coated	  with	  ICAM-­‐1	  mAbs	  was	  
measured	  in	  control	  HMVECs	  or	  in	  HMVECs	  in	  which	  LARG	  expression	  had	  been	  knocked	  down.	  The	  means	  ±	  
SEM	  of	  N≥15	  independent	  bead	  pulls	  are	  shown.	  Asterisk	  shows	  p-­‐value	  of	  statistical	  significance	  by	  t	  test	  
(p≤0.01).	  (E	  and	  F)	  Neutrophils	  were	  added	  to	  a	  monolayer	  of	  TNF-­‐treated	  HMVECs	  after	  LARG	  expression	  
had	  been	  knocked	  down.	  (E)	  Neutrophils	  were	  imaged	  as	  they	  migrated	  over	  the	  HMVEC	  monolayer	  surface	  
and	  their	  velocity	  was	  measured	  using	  tracking	  software.	  Data	  are	  the	  average	  of	  3	  experiments	  with	  ≥15	  
neutrophils	  measured	  per	  experiment.	  (F)	  The	  passage	  of	  neutrophils	  across	  a	  confluent	  EC	  monolayer	  was	  
measured	  using	  transwell	  tissue	  culture	  inserts.	  Data	  are	  the	  average	  of	  3	  experiments	  each	  performed	  in	  
duplicate.	  The	  means	  ±	  SEM	  are	  graphed.	  Asterisk	  shows	  p-­‐value	  of	  statistical	  significance	  (*,	  p≤0.05;	  **,	  
p≤0.01).	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To determine whether ICAM-1-induced stiffening might contribute to 
increased leukocyte migration over the EC surface, we disrupted this pathway by 
knocking down LARG expression. Neutrophils were plated on a TNF-treated EC 
monolayers and live cell imaging was used to calculate the average velocity of 
neutrophil migration. For neutrophils crawling on control knockdown ECs, the 
average velocity was 3 µm/min, whereas after LARG knockdown in ECs the average 
velocity decreased to 2.5 µm/min (Figure 11E).  Given that leukocytes migrate more 
rapidly over stiffer surfaces, these results are consistent with LARG-dependent 
stiffening of ECs induced by neutrophil traction enhancing neutrophil migration over 
the EC surface. 
Endothelial LARG contributes to leukocyte TEM 
To determine whether endothelial LARG contributes to neutrophil TEM, we 
counted and compared the number of neutrophils crossing a control shRNA EC 
monolayer with the number crossing a monolayer in which LARG expression had 
been decreased by shRNA. The percentage of leukocytes crossing the EC 
monolayer after LARG knockdown was decreased by ~35% compared with the 
control EC monolayer (Figure 11F). These results show that LARG activity in ECs 
promotes both neutrophil migration over the endothelial surface as well as neutrophil 
TEM. 
Discussion 
 Leukocyte TEM is an essential step in the recruitment of leukocytes out 
of the blood circulation and into tissues during inflammation. In order for TEM to 
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occur, leukocytes must first adhere to the endothelium and this is mediated by 
receptors on both the leukocyte and ECs. ICAM-1 is a key endothelial receptor 
which functions as a ligand for β2 integrins on the surface of leukocytes, promoting 
leukocyte spreading and migration (6). However, ICAM-1 is more than an adhesive 
ligand, its engagement and clustering by the leukocyte generates many signals in 
ECs that promote TEM (22). It is widely considered that increased RhoA activity 
downstream from ICAM-1 clustering (16, 31) contributes to leukocyte TEM both by 
weakening the junctions and increasing tension on them to open them (15, 22, 23, 
59, 60, 230). At the outset of this work, we were interested in identifying the GEF(s) 
responsible for RhoA activation downstream of ICAM-1, and secondly, we were 
interested in determining whether the tractional forces exerted on ICAM-1 as 
leukocytes migrate affect RhoA signaling. Here we identify LARG as the critical 
RhoA GEF activating RhoA downstream of ICAM-1, show that it is activated by SFK-
dependent tyrosine phosphorylation, and demonstrate that applying mechanical 
force on ICAM-1 clusters equivalent to the forces generated by migrating neutrophils 
enhances this signaling pathway. This is the first report of RhoA activation 
downstream of ICAM-1 being regulated by SFKs. The stiffness of the ECs at ICAM-1 
clusters is of great importance as this is where the leukocyte makes contact with the 
EC, exerts tractional force and senses the EC stiffness. We provide evidence that 
this activation of RhoA not only promotes neutrophil TEM but stiffens the endothelial 
surface which may enhance the migration of neutrophils over it. 
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Our first goal in this work was to identify the GEF(s) downstream from ICAM-1 
responsible for activating RhoA. Several RhoA GEFs have been identified in 
signaling pathways initiated by other cell adhesion molecules. For example, in 
response to integrin-mediated adhesion on fibronectin, p115 RhoGEF and LARG 
were found in one study (102) and p190RhoGEF was implicated in another (107). 
Tension on fibronectin-based adhesions further activated RhoA through LARG and 
GEF-H1 (101). LARG has also been identified in association with CD44 (231), 
whereas p114RhoGEF and GEF-H1 have been associated with tight junctions (104, 
121). Together with p115RhoGEF and PDZ-RhoGEF, LARG belongs to the RGS 
family of RhoA GEFs, implying that it can be activated downstream of G protein-
coupled receptors via binding to Gα12/13. However, it can also be activated 
downstream from integrin engagement as well as following mechanical force on 
integrins (101, 102). In the latter case, activation of LARG was induced by tyrosine 
phosphorylation, either directly or indirectly by the SFK Fyn (101). Downstream from 
ICAM-1 clustering and tension on ICAM-1, we observed that LARG was activated 
and tyrosine phosphorylated in a time course that paralleled RhoA activation and 
that a SFK inhibitor blocked this response. SFKs not only have been shown to be 
activated downstream of ICAM-1 signaling (28, 64, 224) but LARG has also been 
shown to be a substrate of SFKs (101, 232). Knockdown of LARG expression in ECs 
blocked ICAM-1-mediated activation of RhoA, confirming that LARG is critical for 
RhoA activation downstream of ICAM-1. We found that p115RhoGEF expression 
does increase after LARG knockdown. This increase in p115RhoGEF expression is 
  56 
not sufficient to restore RhoA activity downstream of ICAM-1, however it may well be 
that p115RhoGEF activity compensates for other signaling pathways in the LARG 
knockdown cells.  Our results strongly suggest a pathway in which clustering of 
ICAM-1 activates SFKs that phosphorylate and activate LARG. Our results also 
indicate that mechanical tension on ICAM-1 clusters enhances this pathway leading 
to higher levels of LARG tyrosine phosphorylation, increased activation and elevated 
levels of GTP-loaded RhoA. These findings point to LARG as the major regulator of 
RhoA activity downstream of ICAM-1 signaling.  
Previous studies examining endothelial compliance have obtained conflicting 
results in response to leukocyte adhesion. Initially, using magnetic twisting cytometry 
to pull on integrins, it was found that clustering of ICAM-1 or adhesion of neutrophils 
to ECs induced a stiffening response (233, 234). This is of great interest as it is the 
region of the cell the leukocyte would be in contact with and sensing. In contrast, 
subsequent work by the same group using atomic force microscopy found transient 
and localized softening of the endothelial surface in a zone around where neutrophils 
adhered but an increased stiffening of adjacent cells (235). These differences likely 
result in part from the different techniques used to measure stiffness, but they may 
also reflect slight differences in culture conditions with the former favoring 
paracellular transmigration (i.e. passage through the junctions) and the latter 
favoring transcellular migration (i.e. passage through the EC body). Atomic force 
microscopy has also been used to show that treatments, such as TNF, or plating 
ECs on stiffer substrata, increase EC stiffness (236, 237). While there have been 
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many studies looking at the role of EC behavior on substrata of different stiffness 
(237-241), here we observe that ECs alter the stiffness of their points of contact with 
leukocytes in response to tractional force generated by the leukocyte. The EC 
response we observe is independent of the type of ECM protein to which the ECs 
adhere.  In the context of leukocyte migration, stiffer substrata have been linked to 
enhanced leukocyte crawling, adhesion and the generation of stronger tractional 
forces (226, 227, 242, 243). The finding that mechanical force on ICAM-1 induces a 
LARG-dependent endothelial stiffening provides a novel mechanism by which 
leukocytes can manipulate ECs to facilitate leukocyte TEM. 
The recruitment of leukocytes from the blood circulation and into tissues is 
critical in the inflammatory response that contributes to defense of the host organism 
against invasion by infectious or other foreign agents. However, inappropriate 
recruitment and activation of leukocytes underlies many acute or chronic 
inflammatory diseases. In the search for new therapeutic targets to combat 
inflammatory diseases, strategies to inhibit leukocyte TEM continue to be 
investigated. Our finding here that inhibiting LARG in ECs decreases TEM, suggests 
that LARG may be a suitable anti-inflammatory target that is more specific than 
targeting RhoA activity itself which has diverse functions in many cells. Several 
studies have recently aimed at developing inhibitors of GEFs including LARG (244, 
245), making this an exciting direction to pursue in the future. 
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Methods and materials 
 
Reagents and antibodies 
RhoA mAb and ICAM-1 mAb (western blotting) were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). The mAb against MHC class I (HLA-A, -B, 
and -C) was purchased from BD Biosciences (Franklin Lakes, NJ). The pAb for 
LARG (for immunoprecipitation) was purchased from Abcam (Cambridge, MA). 
Phosphotyrosine mAb, clone 4G10, Y-27632, SU6656, and blebbistatin were 
purchased from Millipore (Billerica, MA). pAb for p115, and phosphorylated myosin 
light chain (pMLC) (Thr18/Ser19) were purchased from Cell Signaling (Danvers, 
MA). pAb for LARG, and PDZ-RhoGEF were made against the c-terminal tail of the 
proteins (Pocono Rabbit Farm and Laboratory, Canadensis, PA). Recombinant TNF 
and stromal cell–derived factor-1 (CXCL12) was purchased from R&D Systems 
(Minneapolis, MN). aICAM-1 R6.5.D6 hybridoma was purchased from ATCC 
(Manassas, VA). mAb for tubulin, mAb for myosin light chain (MLC), and 
Cytochalasin D, were purchased from Sigma-Aldrich (St. Louis, MO). pAb for 
GEFH1was purchased from Bethyl (Montgomery, TX). mAb for myc was purchased 
from Invitrogen (Grand Island, NY). Bovine Collagen Solution was purchased from 
Advanced BioMatrix (San Diego, CA). Fibronectin was isolated from human plasma 
as previously described (102). pAb for p190RhoGEF (Rgnef) was a generous gift 
from Dr. David D. Schlaepfer (University of California San Diego).  
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Cell cultures and treatments 
Neonatal human dermal blood microvascular ECs (HMVEC), pooled HUVEC, 
growth medium and supplements were purchased from Lonza (Walkersville, MD). 
ECs were cultured at 37oC and 5% CO2. For all experiments, unless otherwise 
noted, HMVEC were grown on 10 µg/ml collagen until confluent for at least 24 h. For 
all biochemical experiments at least 104 mAb-coated beads were added per cm2. For 
all magnetic tweezer experiments at least 103 beads were added per cm2. Static 
force was applied by placing a ceramic magnet above the tissue culture dish for the 
specified length of time. Primary human neutrophils were isolated from donor blood 
drawn by BD Vacutainer ® CPT Cell Preparation Tubes (BD Biosciences) following 
the manufacture’s protocol. Briefly, whole blood was spun for 15 min at 15,000 g. 
The granulocyte and red blood cell fractions were recovered and the RBCs lysed. 
The remaining neutrophils were re-suspended in complete EC medium containing 
1% Human serum albumin and 1 mM HEPES. Institutional Review Board for 
University of North Carolina at Chapel Hill has approved all human subject protocols. 
 
mAb-coated beads and force with the permanent magnet 
aICAM-1 R6.5.D6 hybridomas were grown in Cell mAb Serum Free Media 
(BD Biosciences) in CELLine CL-1000 Flasks (BD Biosciences) and the Ig was 
purified from the hybridoma culture supernatant using a Protein AG UltraLink Resin 
(Thermo Fisher Scientific, Waltham, MA). Purified mAb was dialyzed in 0.1 M borate 
  60 
buffer, pH 9.5. Tosyl-activated Dynabeads M-450 Beads (Invitrogen, Carlsbad, CA) 
were prepared following the manufacturer’s protocol. Briefly, beads were washed 
twice with 0.1 M borate buffer pH 9.5 and incubated with 1 µg/ml mAb per 106 beads 
in 0.1 M borate buffer pH 9.5 at 37oC. After 30 min fatty acid-free BSA was added for 
a final concentration of 0.01% and rotation continued overnight. For all biochemical 
experiments, a continuous force (~10 pN) was applied to mAb-coated beads using a 
permanent ceramic magnetic (K&J Magnetics, Jamison, PA) 1 cm above and 
parallel to the monolayer of ECs in the tissue culture dish. 
 
Magnetic tweezer force assay 
mAb-coated beads were added to ECs for approximately 10-20 min and bead 
tracking was initiated. Pulses of force (~160 pN) were applied on the beads using 
the UNC three-dimensional force microscope. The magnetic tweezers were 
positioned ~25 microns above the monolayer (so as to avoid scraping the underlying 
monolayer of cells). Force was applied to individual beads at an acute angle.  Cells 
were imaged using an 40x objective (Olympus UplanLN 40x/.75) on an Olympus 
IX81®-ZDC2 inverted microscope (Olympus) equipped with a high-speed Rolera 
EM-C2 camera (QImaging) to record bead movement using MetaMorph software at 
30 frames per second. Bead movements above 70 nm were tracked by Video Spot 
Tracker (Center for Computer Integrated Systems for Microscopy and manipulation, 
http:// http://cismm.cs.unc.edu).  Before experiments began, the magnetic tweezer 
system was calibrated by applying a force ramp to magnetic beads in a Newtonian 
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fluid of a known viscosity. By recording bead trajectories and computing bead 
velocities, Stokes law, F = 6πaηv, was used to determine the force, where a is the 
bead radius, η is the fluid viscosity, and v is the bead velocity. Knowledge of the 
bead displacement r(t) and the applied force F(t) allowed for computing the 
compliance signature, J(t) = 6πar(t)/F(t),which was then fit to a modified Kelvin-Voigt 
mechanical circuit model for viscoelastic liquids. The spring constant was reported 
as the local stiffness in pascals (Pa).  
 
Preparation of recombinant proteins 
pGEX GST-RBD and pGEX GST-RhoAG17A fusion proteins were prepared 
from lysates from Bl21 Escherichia coli cells induced with 100 µM IPTG for 16 h at 
RT. For GST-RBD, bacterial cells were lysed in 20 mM Tris pH 7.8, 1% Triton 100, 
10 mM MgCl2 1 mM DTT, 1mM PMSF, and 10 µg/ml aprotinin and leupeptin. For 
GST-RhoAG17A bacterial cells were lysed in 20 mM HEPES pH 7.8, 150 mM NaCl, 
10 mM MgCl2, 1mM PMSF, and 10 µg/ml aprotinin and leupeptin. The recombinant 
proteins were isolated from the bacterial lysates by incubating with glutathione-
Sepharose 4B beads (GE Healthcare) at 4oC for 4 h. The beads were sedimented 
and washed 3 times in 20 mM HEPES, pH 7.5; 150 mM NaCl, 1 mM DTT. 
 
GST-RBD and GST-RhoAG17A Pull-down Assay 
RhoA activation assays were preformed as described (183). HUVECs were 
lysed in 300 µL of 10 mM MgCl2, 500 mM NaCl, 50 mM Tris, pH 7.8, 1% Triton X-
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100, 0.1% SDS, 0.5% deoxycholate, 1mM PMSF, and 10 µg/ml aprotinin and 
leupeptin, cleared at 14,000g at 4oC for 3 min and incubated with at least 20 µg of 
GST-RBD for 20 min at 4oC. Beads were then washed 3x in 50 mM Tris, pH 7.4, 10 
mM MgCl2, 150 mM NaCl, 1% Triton X-100, 1mM PMSF, and 10 µg/ml aprotinin and 
leupeptin. Active GEFs were assayed by binding to GST-RhoAG17A as described 
(229). In short it was performed as the RhoA activation assays with the following 
changes. HUVECs were lysed in 150 mM NaCl, 20 mM HEPES, pH 7.6, 10 mM 
MgCl2, 1% Triton X-100 1mM PMSF, and 10 µg/ml aprotinin and leupeptin, and 
incubated with GST-RhoAG17A beads for 60 min at 4oC and washed in the same lysis 
buffer. Samples were then analyzed by western blotting. 
 
Western Blotting 
Samples were run on SDS-PAGE gels and transferred to polyvinylidene 
fluoride membranes (Millipore). Membranes were blocked and incubated with the 
specified primary antibodies followed by species-specific secondary antibodies 
conjugated with horseradish peroxidase. Blots were developed with a 
chemiluminescent HRP substrate, and visualized on x-ray film. For quantification, 
blots were scanned and the intensity values determined using Image J software 
(NIH) and protein levels were normalized to control protein levels. All quantification 
graphs include ≥3 independent experiments. Error bars represent SEM. 
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Phase contrast microscopy 
HUVECs were grown on collagen-coated coverslips for at least 72 h before imaging. 
HUVECs were treated with 5 ng/ml TNF overnight. Beads were added for 15 min 
then unbound beads were washed off. Cells were fixed with 3.7% paraformaldehyde 
and mounted on coverslips. Coverslips were then imaged using a 20x objective 
(Zeiss plan-Apochromat 20x/ 0.8) with a Zeiss axiovert 200 M microscope with a 
Hamamatsu ORCA-ERAG digital camera and MetaMorph software.  
 
Immunoprecipitation  
HUVECs were lysed on ice for 30 min in lysis buffer (10 mM Tris, pH 7.4, 150 
mM NaCl, 1% Triton X-100, 0.5% NP-40, containing 1mM PMSF, and 10 µg/ml 
aprotinin and leupeptin, and 10 µg/ml orthovanadate). Lysates were precleared with 
protein A/G-agarose beads, and then incubated with LARG pAb overnight at 4 °C. 
A/G-agarose beads added for 1 h at 4 °C, then were sedimented and washed in lysis 
buffer at 4°C, resuspended in sample buffer, boiled for 10 min, and analyzed by  
Western blotting.  
 
Viral shRNA Knockdown of protein expression 
The targeted sequence for LARG was GCGAGTATCCAGAGAAGGAAT and 
prepared by the UNC lenti-shRNA core. ECs were grown to 80% confluency and 
infected with the lowest amount of viral particles to ensure sufficient knockdown at 
48 h. Infected cells were then selected with 2.5 µg/ml puromycin for 24 h. For 
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biochemical experiments, ECs were allowed to grow until confluent. For imaging 
experiments ECs were re-plated at confluence. RhoA knockdown re-expression was 
achieved using adenovirus miRNA and WT RhoA re-expression as previously 
described (246). After knockdown and RhoA rescue, cells were re-plated at a high 
density for experimental assays. 
 
Electrical impedance measurement of monolayer integrity 
After puromycin selection, high density HMVECs were plated on SIM plates 
(Roche Applied Science) coated with 6 µg/ml collagen. Electrical impedance was 
measured using the xCELLigence Real-Time Cell Analyzer (RTCA) system (Roche 
Applied Science). Each experiment was performed in triplicate and repeated 3 times.  
 
Live-cell imaging 
HMVECs were grown on collagen-coated glass dishes (MatTek Corporation) 
for at least 72 h before imaging. HMVECs were treated with 5 ng/ml TNF overnight. 
Neutrophils were added for 10 min then unbound cells were washed off. Cells were 
then imaged at 37°C and 5% CO2 using a 20x objective (Zeiss plan-Apochromat 
20x/ 0.8) with a Zeiss axiovert 200 M microscope with a Hamamatsu ORCA-ERAG 
digital camera and MetaMorph software for 30 min in EC growth medium. A manual 
tracking plug-in (http://rsbweb.nih.gov/ij/plugins/track/ track.html) for Image J 
software (NIH) was used to determine cell migration velocities. 
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TEM assay 
TEM assays were performed in transwell plates (Corning, Corning, New York, 
U.S.) of 6.5-mm diameter with 8-μm pore filters. HMVECs were plated to generate a 
confluent monolayer on collagen-coated transwell filters and treated with 5 ng/ml 
TNF overnight. Neutrophils were added to the upper chamber and allowed to 
migrate across the monolayer to 25 ng/ml CXCL12 for 1 h at 37°C and 5% CO2. The 
filters were fixed, stained with DAPI and neutrophils that had migrated to the lower 
chamber were counted by fluorescence microscopy using a 20x objective (Zeiss 
plan-Apochromat 20x/ 0.8) with a Zeiss axiovert 200 M microscope with a 
Hamamatsu ORCA-ERAG digital camera and MetaMorph software. The experiment 
was preformed four times in duplicate. 
Statistical analysis  
Statistical significance of data was determined using a two-tailed unpaired t 
test. 
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Chapter 4: CONCLUSIONS AND FUTURE DIRECTIONS 
Summary 
At the outset of this research, we had two goals. First, we sought to identify a 
role for mechanical force in ICAM-1 signaling, and second to identify the GEF 
responsible for the RhoA activation. There is a growing body of research looking the 
role for mechanical force on cells leading to RhoA activation (reviewed in Chapter 2). 
The results presented in Chapter 3 illustrate that mechanical force on ICAM-1 alters 
EC stiffness via the RhoA pathway (Figure 12). Mechanical force on ICAM-1 leads to 
an increase in RhoA activity and actomyosin contraction via the ROCK pathway 
causing cells to become stiffer. The increase in cellular stiffness at ICAM-1 clusters 
increases leukocyte crawling velocity and TEM. We also identified LARG as the 
upstream GEF regulating RhoA activity after ICAM-1 clustering. Applying mechanical 
force on ICAM-1 clusters leads to a further increase in LARG activation and 
phosphorylation. After depleting cells of LARG, there was a decrease in leukocyte 
crawling velocity and TEM, as well as a loss of the adaptive cellular stiffening after 
pulses of force on ICAM-1.  
These findings are valuable as they look at a role of ICAM-1 signaling in ECs 
exposed to physiological forces. Previous studies looking at ICAM-1 signaling used 
static clustering of ICAM-1 and neglected the role of tractional forces generated by 
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the crawling leukocyte. We document that these forces are important for EC 
signaling during leukocyte TEM. 
Figure	  12:The	  Pathway	  downstream	  	  
from	  mechanical	  force	  on	  ICAM-­‐1	  
Substratum Stiffness  
 Pulling on ICAM-1, like a leukocyte would, 
induces EC stiffening as presented in chapter 3. 
Knocking down LARG prevents the adaptive 
stiffening response. Also, we observe that the 
leukocyte crawling velocity is reduced as well as 
leukocyte TEM (Figure 11). This is assumed to be a 
result of a suboptimal compliance of the EC for the 
crawling leukocyte. While substratum compliance 
has previously been shown to alter cell migration 
(226, 227, 242, 243), the effect of the compliance of 
an EC on crawling leukocytes has not been examined. Even measuring the EC 
compliance during leukocyte TEM or ICAM-1 clustering is difficult. Conflicting 
observations about how EC compliance changes are likely due to varying methods 
and locations on the EC surface used to determine the compliance (233-235), as 
discussed in Chapter 3. Based on the work documented in Chapter 3, we would 
predict that leukocytes crawling on ICAM-1 prefer a stiffer substratum. Addressing 
this question, proved to be more difficult than expected. Plates coated with a 
polyacrylamide hydrogel of different compliances ranging from 0.2-50 kPa are 
commercially available and easily coated with recombinant extracellular ICAM-1. 
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However, leukocyte adhesion and spreading is greatly affected by stiffness and 
concentration of ICAM-1 coating. I found that leukocytes did not adhere or spread 
similarly with a constant concentration of ICAM-1 on substrates of different 
compliance. Leukocytes either did not adhere or if they adhered did not crawl 
despite being in the presence of a chemoattractant CXCL12. Various conditions 
were tested included plates with a compliance of 8, 12, 25, or 50 kPa and ICAM-1 
concentration ranging between 10-100 ng/ml. Lowering the coating concentration of 
ICAM-1 was able to induce some leukocyte crawling on the stiffer plates (12-50 kPa) 
but using the same concentration on a softer plate was insufficient for leukocytes to 
adhere and spread. However due to the cost of the dishes, a limited number of 
attempts at this experiment were made. Notably, this in vitro system to mimic the 
surface of an EC lacks other adhesion receptors that are normally present. It is likely 
that there is cross-talk among the adhesion receptors. Adding other adhesion 
molecules or more extensive testing of conditions could improve leukocyte initial 
adhesion, allowing the subsequent crawling velocities to be compared. Although, it is 
possible that regardless of the conditions, a softer substratum will always impair 
leukocyte adhesion. The results in Figure 11 show the initial stiffness between 
control and LARG knockdown was not statistically different (Figure 11E). There is a 
change in stiffness with the second pulse (Figure 11F). There is not a leukocyte 
adhesion defect to ECs lacking LARG. Perhaps this is because LARG knockdown 
does not change the initial compliance. To accurately address this question using an 
artificial substratum we need to have dishes with an adjustable compliance. 
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Although, these results do show that substratum stiffness regulates leukocyte 
adhesion to ICAM-1 coated surfaces. Without being able to keep the coating 
concentration of ICAM-1 constant and have similar initial leukocyte adhesion and 
spreading, it is impossible to look at the later stage of leukocyte crawling and to 
compare velocities in a meaningful way.  
Other Rho Family GTPase 
 While RhoA is the most-well studied Rho GTPase downstream of ICAM-1, 
Rac and RhoG are also involved in ICAM-1 signaling. van Buul  et al. documented 
that Rac and RhoG are activated after ICAM-1 clustering (30). Rac activation occurs 
10 min after clustering whereas RhoG activity peaks later at 30 min. Looking at the 
time points in Figure 8A, Rac and RhoG activation are unchanged with mechanical 
force compared to clustering alone (Figure 13A). Clustering alone did increase Rac 
activation. Since peak RhoG activation is delayed after ICAM-1 clustering, a longer 
time point of 30 min of ICAM-1 clustering is also considered (Figure 13B). While 
RhoG activity is stimulated after longer periods of ICAM-1 clustering, there is no 
further increase with the application of force for 1 min. These results suggest that the 
force response affects RhoA and does not involve Rac or RhoG. This is intriguing 
because RhoA appears to be upstream of ICAM-1-dependent RhoG activity (30). 
RhoA could be a central regulator in directing leukocyte diapedesis via paracellular 
or transcellular migration. Additionally, it is possible that Rac or RhoG might be 
critical in the recovery response. While not studied here, recovery and junction 
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reformation is vital during acute damage or inflammation. It is possible for Rac, and 
maybe RhoG, to be involved in this later process. 
Figure	  13:	  Mechanical	  force	  on	  ICAM-­‐1	  does	  not	  alter	  other	  Rho	  family	  GTPases	  
Magnetic	  beads	  coated	  with	  mAb	  against	  ICAM-­‐1	  (A,	  B)	  were	  added	  for	  15	  min	  (A)	  or	  30	  min	  (B)	  to	  a	  
monolayer	  of	  TNF-­‐treated	  HUVECs	  and	  ~10	  pN	  force	  was	  applied	  with	  a	  ceramic	  magnet	  placed	  above	  the	  
cells	  for	  1	  min.	  (A)	  Using	  GST-­‐PBD	  or	  GST-­‐ELMO,	  Rac.GTP	  or	  RhoG.GTP,	  were	  isolated	  and	  detected	  by	  
immunoblotting.	  (B)	  Using	  GST-­‐ELMO,	  RhoG.GTP	  was	  isolated	  and	  detected	  by	  immunoblotting.	  	  	  
 
LARG Signaling 
 We showed that endothelial LARG mediates ICAM-1 signaling leading to 
RhoA activation, and that this contributes to leukocyte crawling and TEM. 
Traditionally, GPCR signaling activates LARG (45). Our research is among a 
growing body of work showing LARG regulating RhoA activity downstream of 
adhesion molecules (102) and mechanical force (101, 228). However, the exact 
mechanism leading to LARG dependent cellular stiffening appears to be different 
depending on the adhesion receptor. Guilluy et al. show that LARG is downstream of 
integrin signaling mediated by the src family kinase Fyn to induce cellular stiffening 
(101). Collins et al. show that LARG is involved in PECAM-1 signaling. 
Hemodynamic forces on PECAM-1 lead to phosphatidylinositol 3-kinase-dependent 
signaling to integrins, RhoA activation, new focal adhesion formation and cellular 
stiffening (228). LARG activity downstream of ICAM-1 is not dependent on 
engagement of specific integrins as the same response is seen with ECs adhering to 
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fibronectin and collagen (Figure 7 B and C), instead it is likely a more local response 
at the site of ICAM-1 clustering. Also, GEF-H1 does not appear to be involved in 
ICAM-1 signaling (Figure 9D). These differences suggest that adhesion receptors 
use different signaling pathways to activate RhoA but many of these may converge 
on LARG to increase RhoA activity. This is expanding the role of LARG beyond 
GPCR signaling. However, much about LARG signaling remains unknown.   
LARG as a Mechanosensor   
The repeated finding of LARG being activated by mechanical force is 
intriguing. Is LARG itself a mechanosensor?  Mechanical force on the ICAM-1 
complex, or on other adhesion complexes, might physically alter LARG and expose 
new binding sites within this GEF. Given that LARG is activated downstream of force 
application on many adhesion receptors, this suggests that LARG might be a 
mechanotransducer. The exact signaling pathway leading to LARG activity after 
mechanical force varies depending on the surface receptor. Applying force on LARG 
might expose new phosphorylation sites or binding sites allowing it to become more 
active. Although, it is equally possible that an intermediate mechanosenstive protein 
in the ICAM-1 complex becomes more activated, increasing Src or a SFK activity 
which then increases LARG phosphorylation. 
Knockout mice 
 The results presented in Chapter 3 show a new role of LARG in leukocyte 
TEM, however these findings have not been confirmed in vivo. The first publication 
examining mice lacking LARG found a conditional knockdown of LARG in smooth 
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muscle cells were deficient in MLC signaling in smooth muscle cells leading to an 
prevention of ca+ included hypertension (247). This RhoA signaling pathway is most 
likely downstream of G12-G13, as mice deficient in G12-G13 have a similar 
phenotype(247). Despite LARG having distinct expression during development and 
widespread expression in adult tissues (248), the initial report of LARG deficient 
mice reported no obvious phenotype (247). A further analysis found while mice 
lacking LARG appear to be normal, crossing Larg+/- mice with Larg+/- mice produce 
fewer Larg-/- births than expected suggesting that LARG deficiency might be lethal 
but with compensation from other GEFs or via another mechanism a subset of mice 
can still develop normally (38). To further support this, mice lacking both LARG and 
its close family member PDZ-RhoGEF are not viable beyond E10.5, likely due to a 
developmental defect in blood vessel formation (38). To date, there have been no 
reports examining leukocyte TEM in the LARG deficient mice or a conditional double 
LARG and PDZ-RhoGEF deficient mice.  
The in vivo role of ICAM-1 in leukocyte TEM has been measured by injecting 
pro-inflammatory reagents and measuring leukocyte migration into tissues using 
ICAM-1 null mice (249). Alternatively, there are more physiological models, like 
pathogenic infections (89, 250, 251) or atherosclerosis models (252-254), using 
mice with or without ICAM-1 to measure ICAM-1-dependent leukocyte TEM. A 
similar approach could be used with the LARG-deficient mice to confirm in vivo the in 
vitro results in chapter 2.  
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However, using the LARG-deficient mice with any of these models could be 
problematic and perhaps provide conflicting results for several reasons. One reason 
is that while LARG appears to be involved in vascular biology it is not EC specific 
(38, 247, 248). The role of LARG in leukocytes has been well establish as LARG is 
named Leukemia-associated Rho guanine nucleotide exchange for its role in acute 
myelogenous leukemia by genetic rearrangement between LARG and mixed lineage 
leukemia (MLL) genes to express a LARG-MLL fusion protein (255). Therefore, to 
study LARG in vivo either an EC-specific LARG knockout mouse needs to be 
developed or the LARG null mouse needs to be reconstituted with wildtype 
leukocytes. There is a chance that the remaining LARG-deficient leukocytes could 
confound the results. 
The other complicating factor with looking at the role of LARG in vivo, is the 
compensation from other GEFs. PDZ-RhoGEF and LARG deficient mice have a 
more dramatic phenotype than the single knockdown (38). Leukocyte TEM is a 
conserved process for both the innate and adaptive immune response, which can be 
critical for survival. Therefore, there is a high chance of compensation with other 
GEFs like PDZ-RhoGEF, p115RhoGEF or other RhoA GEFs. It is assumed the 
LARG deficient mice that make it to adulthood already have a compensatory 
mechanism occurring. Therefore it is reasonable to predict that the LARG deficient 
mice will lack a noticeable defect in leukocyte TEM. An EC specific single or double 
GEF knockout mouse would be a better model. There is still a chance the EC  
specific double GEF knockout mouse might not be viable since the global knockout 
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has a lethal vascular defect (38). These experiments would be the next step for this 
project to confirm a role for LARG in vivo for leukocyte TEM. However, this is not a 
trivial undertaking and could be a lengthy endeavor, which is why I was unable to 
address the matter. 
Role in Cell Spreading 
The regulation of cell shape by LARG is a finding not discussed in Chapter 3. 
After LARG knockdown, the overall spreading area of ECs increased (Figure 14A, 
B). To date, these observations have not been methodically studied. Preliminary 
results point to a spreading defect in ECs lacking LARG. After LARG knockdown, 
there is no observed change in junction formation (Figure 9). Also, we saw normal 
endothelial cell-cell junctions measured by β-Catenin staining (Figure 14A). ECs 
after control or LARG knockdown have on average the same diameter in suspension 
(Figure 14C). Normally when ECs become a monolayer they continue to divide for a 
short period of time to allow a tightly packed monolayer to develop. Based on my 
observations, I suspect that after LARG knockdown cells become confluent they stop 
proliferating. In subconfluent cells there does not appear to be an initial proliferation 
defect (Figure 14D and E). However, there is a published report that LARG 
knockdown in Hela cells results in a cell division defect (256). All of the observations 
presented in Chapter 3 and 4 use ECs right after LARG knockdown. Typically, cells 
were treated with lenti-shRNA virus in the experimental dish at near confluency or 
trypsized a single time then plated at high density in the experimental dishes. After, 
long-term knockdown of LARG, ECs did stop growing. However, since Hela cells 
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grow faster and continue to divide after confluency, this might explain why we did not 
see cell death and apoptosis in our experiments.  
 
Figure	  14:	  LARG	  knockdown	  alters	  cells	  spreading	  
HUVECs	  were	  treated	  with	  control	  or	  LARG	  shRNA	  lenti-­‐virus	  for	  48	  h	  and	  selected	  with	  2.5	  ng/ml	  
puromycin	  for	  24	  h.	  (A)	  ECs	  were	  than	  plated	  on	  fibronectin	  coated	  coverslips	  for	  48	  hoursCells	  were	  fixed	  
then	  stain	  for	  β-­‐Catenin.	  (B)	  The	  average	  area	  was	  calculated	  and	  graphed.	  The	  means	  ±	  SEM	  of	  ≥6	  fields	  of	  
view.	  Asterisk	  shows	  p-­‐value	  of	  statistical	  significance	  by	  t	  test	  (*,	  p≤0.05).	  C)	  ECs	  were	  trypsinized	  and	  the	  
mean	  diameter	  was	  calculated.	  The	  means	  ±	  SEM	  of	  ≥4	  fields	  of	  view.	  (D	  and	  E).	  	  
 
Conclusions 
We have confirmed that mechanical force on ICAM-1, like that of a crawling 
leukocyte, leads to changes in ECs via the RhoA pathway. Specifically, we see that 
RhoA activity is increased in response to force on ICAM-1 clusters, as is cellular 
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stiffening. We have determined that the GEF responsible is LARG. This is the first 
report of endothelial LARG regulating leukocyte crawling and TEM. 
The work presented in this thesis has focused on signaling downstream of 
ICAM-1 and mechanical force. During leukocyte TEM, multiple adhesion receptors 
are engaged and receptor cross-talk occurs. Do other adhesion receptors respond to 
leukocyte generated mechanical force? It is likely that other adhesion receptors 
which bind the moving leukocyte will response to the physical force generated by the 
leukocyte. While E-selectin and V-CAM-1 are obvious candidates, there are also 
less well studied receptors like Thy1 (CD90) that should be considered. Thy1 is 
expressed on the surface of ECs during inflammation (257). Thy-1 is also implicated 
in leukocyte TEM (257-259). and Rho GTPase signaling (260-262). Also, does force 
on one of these receptors, like ICAM-1, alter the signaling pathways of other 
adhesion receptors. By expanding on this work to include other EC adhesion 
receptors we can start to fully understand the signaling that occurs during leukocyte 
TEM.  
Historically, when we try to work out the signaling mechanism in an in vitro 
system we frequently neglect how the cell’s 3D environment might be contributing to 
the signaling pathways. Cells in vivo are constantly experiencing physical forces 
generated by cell tension, neighboring cells, or other external cues like 
hemodynamic forces. It is important not to overlook the role these forces will have on 
the cellular behavior. 
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